PHILLY
Advanced Cell and Gene Therapy in Philadelphia

Registration
webpage:atphilly.org/

美中藥協 SAPA
Philadelphia 费城
sapagp.org

2023 @PHILLY CELL AND GENE THERAPY ANNUAL CONFERENCE

This meeting brings together the innovators and business leaders to foster collaborations and advance cell and gene therapeutics in the Greater Philadelphia area

@Philly Forum: The Business of Saving Lives
THE CHAMBER of Commerce for Greater Philadelphia
Scientific Track - Discovery, CMC, Clinical/Regulatory
Business - Expert-led Roundtables and Entrepreneur Essentials

23-24 June, 2023
Sheraton Valley Forge Hotel, 480 N Gulph Rd, King of Prussia, PA 19406

A WELCOME LETTER FROM CONFERENCE CO-CHAIRS

Dear Colleagues,

Welcome to the 2023 @Philly Cell and Gene Therapy Annual Conference, organized by SAPA-GP. With this great gathering, we celebrate the greater Philadelphia region's decades long legacy as a global leader in cell and gene therapy, which includes groundbreaking milestones such as the first cell therapy (Kymirah®) and the first gene therapy (Luxturna®) approvals by FDA. In this conference, attendees will engage in lively discussions and explore innovative opportunities. By bringing together scientists, entrepreneurs, and business leaders, the conference serves as an excellent platform to foster scientific collaborations, forge business partnerships, and promote the advancement of the cell and gene therapy field in the greater Philadelphia area.

We extend our warm welcome to our esteemed keynote speakers, including James Wilson, MD, PhD, Professor at the Perelman School of Medicine at the University of Pennsylvania; Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research at the FDA; Federico Mingozzi, PhD, Chief Science & Technology Officer at Spark Therapeutics; Katherine High, MD, Visiting Professor at Rockefeller University in New York; and Sheila Mikhail, JD, MBA, Co-Founder and Former CEO of AskBio. The two-day in-person conference will be packed with inspiring stories and constructive discussions that delve into wide-ranging topics from drug discovery to the vibrant local biotech ecosystem that fosters the growth of both talents and assets of cell and gene therapies.

In addition, the conference features the exciting @Philly Forum, organized in collaboration with the Chamber of Commerce for Greater Philadelphia. The forum aims to highlight greater Philadelphia's strengths in cell and gene therapy research, development, manufacturing, and entrepreneurship, with a particular focus on government policy, business environment, and investment. Attendees will explore the region's competitive advantages and identify opportunities for growth, innovation, and sustainable development in the area.

We encourage you to attend the company showcases and visit the exhibit area to learn about our sponsor’s cutting-edge offerings. For current or future founders and business executives, please join our entrepreneur essential panel discussion or participate in expert-led round table discussions on important business topics of the day. These sessions will provide you with valuable knowledge, practical advice, and opportunities to exchange ideas with industry experts and fellow attendees. The receptions held at the end of each day are perfect place for networking and establishing new connections among attendees, industry leaders, and potential collaborators.

In closing, we want to extend a heartfelt thank you to the organizing committee and our dedicated volunteers. Your unwavering commitment and meticulous execution have been instrumental in making this conference a reality. We would also like to express our deepest appreciation to our esteemed speakers and sponsors. We wish you a memorable and fulfilling experience at the conference.

Sincerely,

Haichen Yang, M.D., M.A., M.B.A.
Immediate Past President SAPA-GP 2022-23; Conference Co-Chair

Yang Yuan, Ph.D., President of SAPA-GP 2023-24; Conference Co-Chair

SPONSORS

WuXi ADVANCED THERAPIES 药明生基

药明康德 WuXi AppTec

QIAGEN

GenScript Make Research Easy

GenScript PROBIO

FORECYTE

AAVnerGene Together We Find The Cures

janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Spark THERAPEUTICS

iCura DIAGNOSTICS

brigene

AskBio

enevoyager

EurekaBio

Polysciences Chemistry beyond the ordinary

MERRILL A BANK OF AMERICA COMPANY

Bristol Myers Squibb™

Jacqueline Chen
Financial Advisor
Senior Portfolio Advisor

Scheer Partners
A Reputation for Results

FRONTAGE

CytoEX

CoJourney

Weinstein and Spellman LLC

SB SinoBiological

南模生物® SHANGHAI MODEL ORGANISMS

2023 @Philly CGT Annual Conference Program-At-A-Glance

DAY1 Jun 23, 2023

8:35 A.M.	Keynote Speech: James M. Wilson, MD, PhD, Director, Gene Therapy Program, Upenn				
9:20 A.M.	Keynote Speech: Peter Marks, MD, PhD, Director, CBER, FDA				
10:05 A.M.	Coffee Break & Networking				
	Gene Therapy	Chemistry, Manufacturing, and Controls (CMC)	@Philly Forum	Expert-Led Roundtable	WuXi Advanced Therapies Sponsored Session
10:25 A.M.	Session 1: AAV-based Gene Therapy: Challenges, Solutions and Future Promise	Session 1: Standing on the Shoulder of Giants: Current CMC Strategy and Future Development Trends	Session 1: Investing a Successful Company in Greater Philadelphia	Session 1: Early Startups Legal Considerations: Structure, Equity, Asset, and Founder's Legal Concerns	Identifying the Right CGT Outsourcing Partner: the WuXi Advanced Therapies CTDMO Model
11:55 A.M.	Lunch Break and Networking / Company Sponsored Lunch Sessions (12:10-1:10 p.m.)				
1:15 P.M.	Keynote Speech: Federico Mingozzi, PhD, MBA, CSO & CTO Spark Therapeutics				
2:00 P.M.	Coffee Break & Networking				
2:15 P.M.	Session 2: The Future of Gene Editing: Advancing Pipeline Development with Different Tools	Session 2: Elite Process Development and Product Characterization	Session 2: Stories behind Decisions to Locate to the Greater Philadelphia	Session 2: Find the Right Match of Investors and Get Their Attention	Company Show Case: QIAGEN
3:45 P.M.	Coffee Break & Networking				
4:00 P.M.	Session 3: Beyond AAV: Exploring Alternative Vectors for Gene Therapy	Session 3: High Quality CGT Manufacturing	Session 3: Navigating CFIUS with Proactive Risk Management	Session 3: Select the Right Location and Make a Good Real-estate Deal	Networking
5:30 P.M.	Reception				
6:00 P.M.	Dinner				
8:00 P.M.					

2023 @Philly CGT Annual Conference Program-At-A-Glance

DAY2 Jun 24, 2023

	Cell Therapy	Clinical Development and Regulatory	RNA Therapy	Expert-Led Roundtable	Company Showcase
8:50 A.M.	Keynote Speech: Katherine High, MD, Visiting Professor, Rockefeller University				
9:35 A.M.	Coffee Break & Networking				
10:00 A.M.	Session 1: Enhancing CAR T Cell Anti-tumor Function Via Bioengineering	Session 1: Unique Challenges in CGT Clinical Trials	Session 1: Novel Delivery Approaches for RNA Therapy	Session 4: Board vs CEO, How to Build a Synergy and Thrive	Wuxi Advanced Therapies (ATU)
11:30 A.M.	Lunch Break and Networking / Company Sponsored Lunch Session (11:50 a.m.-12:50 p.m.)				
1:00 P.M.	Keynote Speech: Sheila Mikhail, JD, MBA, Co-Founder/Former CEO, AskBio				
1:45 P.M.	Coffee Break & Networking				
2:00 P.M.	Session 2: Non-T Cell Immunotherapy Targeting Solid Cancers	Session 2: Evolving Regulatory Landscape	Session 2: mRNA PK/PD	Session 5: The Do and Don't in Getting Out-Licensing Deal Done	Entrepeneurial Essentials: From Bench to Boardroom: The Making of a Biotech Founder/CEO
3:30 P.M.	Coffee Break & Networking				
3:45 P.M.	Session 3: Allogeneic Cell Therapy and Quality Control of Therapeutic Cells	Session 3: Lessons Learned from Recent Success and Trend for Future CGT Drug Development	Session 3: Innovative RNA Modalities Beyond siRNA/ASO/mRNA	Session 6: The Do and Don't in Getting Out-Licensing Deal Done	Networking
5:15 P.M.	Reception				
6:00 P.M.					

AGENDA Friday, June 23rd, 7:45 a.m.-8:00 p.m.

7:45-8:30 a.m.	Check in
Plenary Session	**Grand Ballroom**
8:30-8:35 a.m.	**Opening Remarks & Welcome**
Session chair:	Haichen Yang, M.D., M.B.A., Immediate Past President SAPA-GP 2022-23; Conference Co-Chair; Vice President, Clinical Research, Amicus Therapeutics
8:35-9:20 a.m.	**Keynote speech: The Changing Landscape of Cell and Gene Therapy** James M. Wilson, M.D., Ph.D., Director, Gene Therapy Program, University of Pennsylvania
9:20-10:05 a.m.	**Keynote speech: Expediting the Development and Availability of Gene Therapy** Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, FDA
10:05-10:25 a.m.	**Coffee Break**

10:25-11:55 a.m. Parallel Sessions

Gene Therapy	**Centennial Ballroom 1**
Session 1: AAV-based Gene Therapy: Challenges, Solutions and Future Promise	
Session chair:	Tobias Willer, Ph.D., Director, Amicus Therapeutics
10:25-10:55 a.m.	**Challenges and Promise of AAV-based Gene Therapy: Experience and Case Studies** Chuansong Wang, M.D., Ph.D., Vice President of Process Sciences, Adverum Biotechnologies, Inc.
10:55-11:25 a.m.	**Strategy for Selection of Clinical Doses for a Gene Therapy for the Neurological Disorder Adrenomyeloneuropathy (AMN)** Karen Kozarsky, Ph.D., Chief Scientific Officer & Founder, SwanBio Therapeutics
11:25-11:55 a.m.	**SP-101 Gene Therapy Restores Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Human Cystic Fibrosis (CF) Airway Epithelial Cultures and Drives hCFTRΔR Transgene Expression in the Airways of CF and Non-CF Ferrets** Roland Kolbeck, Ph.D., Chief Scientific Officer, Spirovant Sciences
Chemistry, Manufacturing and Controls (CMC)	**Grand Ballroom**
Session 1: Standing on the Shoulder of Giants: Current CMC Strategy and Future Development Trends	
Session chairs:	Huize Yan, M.S., Process Development Scientist, Spark Therapeutics Jin Wen, Ph.D., Senior Analytical Development Scientist, Spark Therapeutics

10:25-10:55 a.m.	**The Evolution of Recombinant AAV Manufacturing Technology: From Rare Diseases to Common Diseases, From Low Dose to High Dose** Jinpian Diao-Piezunka, Ph.D., EMBA, Head of Technology Development, Spark Therapeutics
10:55-11:25 a.m.	**CMC Considerations and Strategies to Advance Manufacturing/Analytical for Cell Therapy Product** Mandy Xie, Ph.D., Executive Director, Cell Therapy Product & Analytical Development, Bristol Myers Squibb
11:25-11:55 a.m.	**Analytical Challenges for CMC Development for Gene and Cell Therapy Products** Stephen Gacheru, Ph.D., Vice President, Biologics, Gene & Cell Therapy Operations (BGC), Frontage Laboratories, Inc

@Philly Forum — Centennial Ballroom 2

Session 1: Investing a Successful Company in Greater Philadelphia

Session chair: Frederick "Rick" Jones, M.D., M.B.A., Partner, BioAdvance

10:25-11:55 a.m. **Panel Discussion and Q&A**

Panelists:
Bryan Poltilove, MBA, Advisor, BroadOak Capital Partners
Yi-Yen Chen, Ph.D., Associate Director, PCI Ventures, Pen Center for Innovation
Marian Nakada, Ph.D., Vice President of Venture Investment, Johnson & Johnson Innovation – JJDC
Robert Dickey, MBA, Managing Director, Foresite Advisors

Expert-Led Roundtable — Haverford Room

Session 1: Early Startups Legal Considerations: Structure, Equity, and Founder's Legal Concerns

Session chair: Kathleen M. Shay, J.D., Partner, Duane Morris LLP

10:25-11:55 a.m. **Experts:**
Kathleen M. Shay, J.D., Partner, Duane Morris LLP
Rebecca Guzman, J.D., Partner and Vice Chair of M&A Division, Duane Morris LLP

WuXi Advanced Therapies Sponsored Session — Centennial Ballroom 3

Identifying the Right CGT Outsourcing Partner: The WuXi Advanced Therapies CTDMO Model

Session chair: Xuguang Chen, Ph.D., Upstream Process Development Lead, Spark Therapeutics

10:25-10:55 a.m. **WuXi ATU CAR-T and TIL Cell Therapy Platforms Enabling Clients with State-of-the-art Technologies**

Yuxiang Huang, Ph.D., Senior Director, WuXi Advanced Therapies

10:55-11:25 a.m.	**Platform Development and Optimization for Large-scale Lentiviral Manufacture** Yiyu Dong, Ph.D., Associate Director, WuXi Advanced Therapies
11:25-11:55 a.m.	**LentiVector Safety and Regulatory Testing at WuXi Advanced Therapies: Supporting Products from Development to Market** Andreas Solomos, Ph.D., Director, WuXi Advanced Therapies
11:55 a.m.-1:15 p.m.	**Lunch Break and Networking**
Lunchtime Session: GenScript ProBio	**Paoli Room**
Session host:	Tim Zhou, Ph.D., Purification Process Development Lead, Spark Therapeutics
12:10-1:10 p.m.	**Plasmid Manufacturing Strategies for Diverse Therapeutic Candidates** Huiyi Zhu, M.S., Associate Director of Field Application Scientist, GenScript ProBio
Lunchtime Session: uBriGene Biosciences Inc	**Malvern Room**
Session host:	Kelly Pham, Ph.D., Senior Scientist, Merck & Co.
12:10-1:10 p.m.	**One-stop CDMO-Plus Service Provider for CGT** Xiulian Sun, Ph.D., Founder and Chief Technical Officer, uBriGene Biosciences Inc
Lunchtime Session: Liu, Chen & Hoffman LLC	**Bryn Mawr Room**
Session host:	May Huang, CPA, Audit Partner, WWC, P.C.
12:10-1:10 p.m.	**The Corporation Law Every Start-Up Founder Needs to Know** Zhiping Liu, J.D., MBA, Founder, Liu, Chen & Hoffman LLC
Plenary Session	**Grand Ballroom**
Session chair:	Lu Wang, Ph.D., MBA., Process Development Downstream Lead, Spark Therapeutics
1:15-2:00 p.m.	**Keynote speech: Process and Challenges in the Development of In Vivo Gene Therapies with AAV Vectors** Federico Mingozzi, Ph.D., MBA, Chief Science & Technology officer, Spark Therapeutics
2:00-2:15 p.m.	**Coffee Break**

2:15-3:45 p.m. Parallel Sessions

Gene Therapy	**Centennial Ballroom 1**
Session 2: The Future of Gene Editing: Advancing Pipeline Development with Different Tools	
Session chair:	Lili Wang, Ph.D., Research Associate Professor, University of Pennsylvania

2:15-2:45 p.m.	**AAV-Meganuclease-Mediated Gene Targeting Achieves Efficient and Sustained Transduction in Newborn and Infant Macaque Liver** Lili Wang, Ph.D., Research Associate Professor, University of Pennsylvania
2:45-3:15 p.m.	**Somatic in Vivo Therapeutic Editing for Cardiovascular and Metabolic Diseases** Xiao Wang, Ph.D., Research Assistant Professor, University of Pennsylvania
3:15-3:45 p.m.	**In Vivo Gene Editing for Treating Lysosomal Storage Diseases** Li (Leo) Ou, Ph.D., Vice President, Genemagic Biosciences

Chemistry, Manufacturing and Controls (CMC) — **Grand Ballroom**

Session 2: Elite Process Development and Product Characterization

Session chair:	John MacNair, Ph.D., Head of Analytical Program Development and Management, Spark Therapeutics
2:15-2:45 p.m.	**AAVone: An All-in-One Plasmid System for Efficient AAV Production** Rongze Yang, Ph.D., Director of Vector Engineering & Production, AAVnerGene Inc
2:45-3:15 p.m.	**Innovations in Viral Vector (AAV) Purification** Ohnmar Khanal, Ph.D., Process Development Downstream Technology Lead, Spark Therapeutics
3:15-3:45 p.m.	**Internal vs External Process Development Strategies for Autologous Cell Therapies and Viral Vectors** Adam Pfendt, M.ChE., Senior Director, Process Development, Carisma Therapeutics

@Philly Forum — **Centennial Ballroom 2**

Session 2: Stories Behind Decisions to Locate to Greater Philadelphia

Session chair:	Matt Cabrey, Founder and Principal Advisor, Growing Greater LLC David Chang, Ph.D., President and CTO of WuXi ATU Lisa Baskin, Sr Vice President, Scheer Partners
2:15-3:45 p.m.	**Panel Discussion and Q&A** Panelists: Sumit Verma, MEM, Sr Vice President Global Strategic Manufacturing, Iovance Jolly Mazumdar, Ph.D., MBA, Co-Founder and former Chief Executive Officer, Chimeron Bio Haishan Xiong, Ph.D., MBA, Chief Executive Officer, Panorama Medicine Susan Chase, Vice President, Business Development, Biolabs Mark Rolfing, M.S., Vice President of Operations, Almac Clinical Services Kate Sullivan, M.S., Vice President of Business Investment and Regional Marketing, The Chamber of Commerce for Greater Philadelphia

Expert-Led Roundtable	Haverford Room

Session 2: Find Right Match of Investors and Get Their Attention

2:15-3:45 p.m.	**Expert:** Bryan Poltilove, MBA., Advisor, BroadOak Capital Partners. Mark Tang, Ph.D., MBA, MPH, Managing Director and Partner, Good Health Capital New York

Company Showcase	Centennial Ballroom 3

Session 2: QIAGEN

Session chair:	Shen Lin, Ph.D., Principal Scientist, Spirovant Sciences
2:15-2:45 p.m.	**Applications and Implementation of a Rapid and Automated Digital PCR Workflow for Cell & Gene Therapy Processing** John Chuckalovcak, M.S., Associate Director, dPCR Business Development, QIAGEN Inc.
3:45-4:00 p.m.	**Coffee Break**

4:00-5:30 p.m. Parallel Sessions

Gene Therapy	Centennial Ballroom 1

Session 3: Beyond AAV: Exploring Alternative Vectors for Gene Therapy

Session chair:	John Easson, M.S., Process Science Leader, Spark Therapeutics
4:00-4:30 p.m.	**Overview of Nonviral Vectors and Delivery Methods** Lauren Woodard, Ph.D., Assistant Professor, Vanderbilt University
4:30-5:00 p.m.	**Beyond AAV: Development of Novel Parvovirus Vectors to Unlock Enabling Pharmacological Attributes** Marc Abrams, Ph.D., Chief Scientific Officer, Carbon Biosciences
5:00-5:30 p.m.	**LNP- a Versatile Platform for Nucleic Acid Delivery** Haoyan (Michael) Zhou, Ph.D., Research Formulation Lead, Spark Therapeutics

Chemistry, Manufacturing and Controls (CMC)	Grand Ballroom

Session 3: High Quality CGT Manufacturing

Session chair:	Zheng Chen, Ph.D., Director, AstraZeneca
4:00-4:30 p.m.	**High-quality Plasmids Manufacturing to Build a Successful Foundation for CGT Product** Lijun Wang, Ph.D., Chief Executive Officer, CoJourney Bio

4:30-5:00 p.m.	**Quality and Regulatory Considerations in the Early Development of iPSC-Derived Effector Cell Manufacturing Process** Eric Law, M.S., Head of CMC Regulatory Affairs, Century Therapeutics
5:00-5:30 p.m.	**Development of a Reliable, High Quality, and cGMP-compliant Lentiviral Vector Biomanufacturing Process** Qinghua (Jenny) Zhao, M.S., Executive Director, Forecyte Bio

@Philly Forum — **Centennial Ballroom 2**

Session 3: Navigating CFIUS with Proactive Risk Management

Session chair:	Fang Shen, Ph.D., Vice President of Research & Translational Biology, Immunome James Fendrick, President & Chief Executive Officer, Rockland Immunochemicals, Inc.
4:00-5:30 p.m.	**Panel Discussion** Panelists: Hugh Davis, Ph.D., Chief Operating Officer & President, Biosion USA, Inc Tom Gordon, MBA, Managing Director, Silicon Valley Bank Zhiping Liu, J.D., MBA, Founder, Liu, Chen & Hoffman LLP Matthew Reber, M.S., MBA, Partner, 1315 Capital James Fendrick, President & Chief Executive Officer, Rockland Immunochemicals, Inc.

Expert-Led Roundtable — **Haverford Room**

Session 3: Select the Right Location and Make a Good Real-Estate Deal

Session chair:	Lisa Baskin, Sr Vice President, Scheer Partners
4:00-5:30 p.m.	**Experts:** Lisa Baskin, Sr Vice President, Scheer Partners Lou Tonon, Sr Associate, Scheer Partners

5:30-6:00 p.m.	**Reception**
6:00-8:00 p.m.	**Dinner (with tickets)** — **Grand Ballroom**

Acknowledgement Presentation

Yufeng Li, Ph.D., President-elect, SAPA-GP 2024-25; Executive Director of Clinical Development, Qilu Pharma

AGENDA Saturday, June 24th, 7:45 a.m.-6:00 p.m.

7:45-8:45 a.m.	Check in

Plenary Session	**Grand Ballroom**
8:45-8:50 a.m.	**Opening Remarks**
Session chair:	Yang Yuan, Ph.D., President of SAPA-GP 2023-24; Conference Co-Chair; Associate Director, Jazz Pharmaceuticals
8:50-9:35 a.m.	**Keynote speech: AAV Gene Therapy: Highlights, Hurdles, and Innovations that will Drive the Future** Katherine High, M.D., Visiting Professor, Rockefeller University
9:35-10:00 a.m.	**Coffee Break and Networking**

10:00-11:30 a.m. Parallel Sessions

Cell Therapy	**Centennial Ballroom 1**
Session 1: Enhancing CAR T Cell Anti-tumor Function via Bioengineering.	
Session chair:	Xianxin Hua, M.D., Ph.D., Professor, University of Pennsylvania
10:00-10:30 a.m.	**CDH17 CAR T Cells Targeting Gastro-Intestinal Solid Cancers** Xianxin Hua, M.D., Ph.D., Professor, University of Pennsylvania
10:30-11:00 a.m.	**Re-invigorating CAR T Cells with Enhanced Anti-tumor Activity via Bioengineering** Leyuan Ma, Ph.D., Assistant Professor, CHOP, University of Pennsylvania
11:00-11:30 a.m.	**Digital PCR-based Methods in Support of CAR T-based New Therapies Development and Testing** Danuta Jarocha, Ph.D., Senior Research Investigator, University of Pennsylvania Joseph A. Fraietta, Ph.D., Assistant Professor, University of Pennsylvania

Clinical Development and Regulatory	**Grand Ballroom**
Session 1: Unique Challenges in CGT Clinical Trials	
Session chair:	Jessica Lee, M.P.H., Vice President Clinical Science and Operations, Spirovant Sciences.
10:00-10:30 a.m.	**Challenges and Opportunities in Clinical Trial Design and Development for Cellular and Gene Therapy Products** Chaohong Fan, M.D., Ph.D., Team Leader of Oncology Branch, DCEO, OTP of CBER, FDA
10:30-11:00 a.m.	**Promises and Challenges of Clinical Development of RNA Therapies** Francesco Bibbiani, M.D., Senior Vice President and Head of Development, Dyne Therapeutics

11:00-11:30 a.m.	**Challenges in Gene Therapy Drug Development** Anh Nguyen, M.D., MBA, Vice President, Sector Lead, AskBio

RNA Therapy — Centennial Ballroom 2

Session 1: Novel Delivery Approaches for RNA Therapy

Session chair:	Tao Niu, Ph.D., Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals
10:00-10:30 a.m.	**Expanding the Scope of RNAi Therapeutics** Vasant Jadhav, Ph.D., Senior Vice President, RNAi Platform, Alnylam Pharmaceuticals
10:30-11:00 a.m.	**Endosomal Escape Vehicle-Oligonucleotide Conjugates for the Targeted Upregulation and Downregulation of Gene Expression** Leo Qian, Ph.D., Co-founder & Vice President, Discovery Research, Entrada Therapeutics
11:00-11:30 a.m.	**Panel Discussion and Q&A** Panel list: Vasant Jadhav, Ph.D., Senior Vice President, RNAi Platform, Alnylam Pharmaceuticals Leo Qian, Ph.D., Co-founder & Vice President, Discovery Research, Entrada Therapeutics

Expert-Led Roundtable — Haverford Room

Session 4: Board vs Chief Executive Officer, How to Build a Synergy and Thrive

Session chair:	Cynthia Cai, MBA, Ph.D., Venture Partner, Viva BioInnovator; President, Tharton Consulting
10:00-11:30 a.m.	**Expert:** Cynthia Cai, MBA, Ph.D., Venture Partner, Viva BioInnovator President, Tharton Consulting

Company Showcase — Centennial Ballroom 3

Session 4: Wuxi Advanced Therapies (ATU)

Session host:	Haichen Nie, Ph.D., Associate Director; Biologics Drug Product Development and Operations; Teva Pharmaceuticals.
10:00-10:30 a.m.	**Globally integrated CTDMO service to enable speedy first-in-human and successful commercialization for CGT companies** David Chang, Ph.D., President and Chief Technology Officer, WuXi ATU

11:30 a.m.-1:00 p.m.	**Lunch Break and Networking**

Lunchtime Session: GenScript	**Malvern Room**
Session host:	Jingwen Niu, Ph.D., Principal Investigator, AlphaThera
11:50-12:50 p.m.	**CRISPR Solutions for non-viral T Cell Engineering** Yang Xiang, Ph.D., Senior Field Application Scientist, GenScript

Plenary Session	**Grand Ballroom**
Session chair:	Yizhen Xu, M.D., Ph.D., Vice President, Clinical Development, AskBio
1:00-1:45 p.m.	**Keynote speech: Equitable Healthcare Affordability and Accessibility: Real Life Examples** Sheila Mikhail, J.D., MBA, Co-Founder/Former Chief Executive Officer, AskBio
1:45-2:00 p.m.	**Coffee Break and Networking**

2:00-3:30 p.m. Parallel Sessions

Cell Therapy	**Centennial Ballroom 1**
Session 2: Non-T Cell Immunotherapy Targeting Solid Cancers	
Session chair:	Dongfang Liu. Ph.D., Associate Professor, Rutgers University
2:00-2:30 p.m.	**From Basic NK Cell Research to CAR-NK Innovation** Dongfang Liu. Ph.D., Associate Professor, Rutgers University
2:30-3:00 p.m.	**Development of CAR Macrophages – A Novel Approach for Solid Tumor Immunotherapy** Michael Klichinsky, PharmD, Ph.D., Chief Scientific Officer, Carisma Therapeutics

Clinical Development and Regulatory	**Grand Ballroom**
Session 2: Evolving Regulatory Landscape	
Session chair:	Li Wan, Ph.D., RAC, Chief Development Officer, Head of Global Regulatory Affairs at GeneQuantum Healthcare
2:00-2:30 p.m.	**Considerations for the Design and Analysis in the Regulation of Cell and Gene Therapy Products** Shiowjen Lee, Ph.D., Deputy Director of the CBER Division of Biostatistics, FDA CBER
2:30-3:00 p.m.	**Regulatory and Clinical Strategy for Development of Second-Generation Gene Therapy for Hemophilia A** Weicheng Wu, Ph.D., RAC., Vice President, Global Regulatory Affairs, ASC Therapeutics, Inc

3:00-3:30 p.m.	**Inspection of Facilities for Gene and Cell Therapy Facilities** Jie He, M.S., Team Lead of CMC Review and Inspection, FDA CBER

RNA Therapy — Centennial Ballroom 2

Session 2: mRNA PK/PD

Session chair:	Tao Niu, Ph.D., Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals
2:00-2:30 p.m.	**Unlocking the Potential of Model Informed Development for RNA Medicines** Husain Attarwala, Ph.D., Vice President, DMPK and Clinical Pharmacology, Aera Therapeutics
2:30-3:00 p.m.	**Considerations for Development and Validation of RT-qPCR Assays in Drug Development** Amanda L. Hays, Ph.D., Scientific Officer, BioAgilytix Labs

Expert-Led Roundtable — Haverford Room

Session 5: The Do and Don't in Getting Out-Licensing Deal Done

Session chairs:	Wendy Pan, J.D., Ph.D., Partner, Goodwin Procter LLP Pan Pan, MBA, Ph.D., Director of Business Development, Akeso Inc.
2:00-3:30 p.m.	**Experts:** Wendy Pan, J.D., Ph.D., Partner, Goodwin Procter LLP Pan Pan, MBA, Ph.D., Director of Business Development, Akeso Inc. Leon "Jun" Tang, Ph.D., Founder/Advisor InScienceWeTrust Bioadvisory, BioSpark Group

Entrepreneur Essential — Centennial Ballroom 3

From Bench to Boardroom: The Making of a Biotech Founder/CEO

Session chair:	Kevin He, MBA, Director of Business Operations, uBriGene Biosciences
2:00-3:30 p.m.	**Experts**: Cynthia Cai, MBA Ph.D., Venture Partner, Viva BioInnovator; President, Tharton Consulting Steve Yang, M.S., MBA, Co-Founder and Chief Executive Officer, Mianus Capital Jimmy Hao, Ph.D., J.D., Partner and Chair of Patent Practice, Fox Rothschild LLP Jolly Mazumdar, Ph.D., MBA, Co-Founder and former Chief Executive Officer, Chimeron
3:30-3:45 p.m.	**Coffee Break**

3:45-5:15 p.m. Parallel Sessions

Cell Therapy — Centennial Ballroom 1

Session 3: Allogeneic Cell Therapy and Quality Control of Therapeutic Cells

Session chair: Yixuan Ming, Ph.D., Downstream Process Development Scientist, Spark Therapeutics

3:45-4:15 p.m. **Off-target Analysis and Genomic Safety of iPSC Derived Allogeneic Cell Therapy Products**

Parimal Pande, Ph.D., Associate Director of Cell Therapy, Johnson and Johnson

4:15-4:45 p.m. **Comparison of Techniques in the Measurement of Cellular Kinetics in Cell Therapy Studies**

Venkata Vepachedu, Ph.D, Associate Scientific Director (Molecular Biology), Janssen Pharmaceuticals Companies of J&J

Clinical Development and Regulatory — Grand Ballroom

Session 3: Lessons Learned from Recent Success and Trend for Future CGT Drug Development

Session chair: Xiaoqing Zhang, M.D., Ph.D., Director, Senior Clinical Trial Physician, Bristol Myers Squibb

3:45-4:15 p.m. **Do Personalized Therapeutic Cancer Vaccines (PTCVs) have a Role in Treating Cancer beyond Adjuvant Settings? DNA Plasmid Based PTCVs for Treating Advanced Liver Cancer Patients**

Niranjan Sardesai, Ph.D., MBA, Co-founder, President and CEO, Geneos Therapeutics

4:15-4:45 p.m. **Clinical Development of HEMGENIX® (etranacogene dezaparvovec) for the Treatment of Adults with Hemophilia B**

Brahm Goldstein, M.D., MCR, Vice President, Research & Development, Hematology, CSL Behring

4:45-5:15 p.m. **Unique Regulatory Consideration for Cell and Gene Therapies**

Snehal Nalik, Ph.D., Head of Regulatory Policy, Regulatory Affairs Leader, Spark Therapeutics

RNA Therapy — Centennial Ballroom 2

Session 3: Innovative RNA Modalities Beyond siRNA/ASO/mRNA

Session chair: Tao Niu, Ph.D., Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals

3:45-4:15 p.m. **Gene Therapy for CNS & Muscle Diseases: tRNA Promises**

Peixin Zhu, Ph.D., Vice President of R&D, Tevard Biosciences

4:15-4:45 p.m. **NHP Validated RNA Editing Therapeutic Pipelines: EdiGene LEAPER Platform**

Pengfei Yuan, Ph.D. Chief Technology Officer, Edigene Inc.

4:45-5:15 p.m. **Panel Discussion and Q&A**

Panel list:
Peixin Zhu, Ph.D., Vice President of R&D, Tevard Biosciences
Pengfei Yuan, Ph.D. Chief Technology Officer, Edigene Inc.

Expert-Led Roundtable **Haverford Room**

Session 6: The Do and Don't in Getting Out-Licensing Deal Done

Session chairs:
Wendy Pan, J.D., Ph.D., Partner, Goodwin Procter LLP
Pan Pan, MBA Ph.D., Director of Business Development, Akeso Inc.

Experts:
Wendy Pan, J.D., Ph.D., Partner, Goodwin Procter LLP
Pan Pan, MBA Ph.D., Director of Business Development, Akeso Inc.
Leon "Jun" Tang, Ph.D., Founder/Advisor InScienceWeTrust Bioadvisory, BioSpark Group

3:45-5:15 p.m.

World Cafe Chat - Networking, Q&A

5:15-6:00 p.m. **Reception**

CONFERENCE ORGANISING COMMITTEE

Leadership Team

Conference Co-Chair	Haichen Yang, Yang Yuan
Program Director	Lu Wang, Yizhen Xu, Saisi Xue, Yufeng Li

Advisory Board

David Chang	Jim Fendrick	Frederick (Rick) Jones	Jing Yang

Operating Committee	**Name**
Marketing/Communication	Jin Wen, Namila
Project Management	Tracy Chen, Shuo Huang
IT/Website	Dian He, Ronghui Zhou
Logistics	Sherry Wang, Yifan Gong
Business Development	Hui Wang
Public Relations	Bill Lu

Track Leads	**Name**
Gene Therapy	Chunjuan (CJ) Song, Yufeng Li
Cell Therapy	Xianxin Hua, Yixuan Ming
CMC	Huize Yan, Jin Wen
Clinical & Regulatory	Yizhen Xu, Li Wan
RNA Therapy	Tao Niu
Business	Jing Yang, Fang Shen, Bill Lu

Session Chairs and Hosts

Andre L Pearson	Cynthia Cai	Dongfang Liu	Jessica Lee	Jingwen Niu	John Easson
John MacNair	Kathleen M. Shay	Kevin He	Lili Wang	Lisa Baskin	Matt Cabrey
May Huang	Pan Pan	Shen Lin	Tim Zhou	Tobias Willer	Wendy Pan
Xiaoqing Zhang	Xuguang Chen	Zheng Chen			

Volunteers

Bradley Zhang	Chenfei Huang	Dengpan Liang	Di Wu	Fei Meng	Holly Meng
Howard Guo	Jake Dong	Jason Xu	Jiahao Xu	Jialie Luo	Jingwen Song
Jiong Wang	Kelly Pham	Laura Nan	Li Chen	Li Ou	Lijun Zhou
Linxuan Yan	Liping Xing	Lirong Yang	Lishan Liu	Lu Zhu	Mia Wu
Minmin Liu	Qi Wang	Rayan Jawa	Ruixi Wang	Ruyu Shi	Sheng Feng
Shi Meng	Shihao Fang	Siven Li	Thomas Yang	Tianying Jiang	Victor Chen
Wenji Lei	Wenzhao Meng	William Wan	Xiao Xu	Xinjun Zhang	Yali Liang
Yan Lei	Yanchun Li	Yangsi Ou	Yanqun Chen	Yifan Bao	Yifang Wang
Yifeng Chen	Yijun Huang	Yingying Sha	Yuan Liu	Yun Liu	Zhiyi Cui
Zhiyuan Sun	Ziru Zhang	Zoey Zheng			

KEYNOTE SPEAKERS

James M. Wilson, M.D., Ph.D.

Director,
Gene Therapy Program
University of Pennsylvania

Rose H. Weiss Professor and Director, Orphan Disease Center Professor of Medicine and Pediatrics Director, Gene Therapy Program Perelman School of Medicine, University of Pennsylvania Co-Founder and Scientific Advisor, Scout Bio Co-Founder and Chief Scientific Advisor, Passage Bio Co-Founder, G2 Bio Co-Founder, Chief Scientific Officer, and Board Member of Institute for Life-Changing Medicine (ILCM) Co-Founder and Chief Scientific Advisor, iECURE Chief Scientific Advisor, Center for Breakthrough Medicines James M. Wilson, MD, PhD, is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare diseases and ways to treat them by gene therapy. Dr. Wilson has published over 600 papers and is named on more than 1200 patents worldwide. The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilsons laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.

Peter Marks, M.D., Ph.D.

Director
Center for Biologics Evaluation and Research, FDA

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and HematologyMedical Oncology training at Brigham and Womens Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development and is an author or co-author of over 100 publications. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Over the past several years he has been integrally involved in the response to various public health emergencies, and in 2022 he was elected a member of the National Academy of Medicine.

Federico Mingozzi, Ph.D., M.B.A.

Chief Science & Technology Officer
Spark Therapeutics

Dr. Federico Mingozzi is the Chief Science & Technology officer at Spark Therapeutics. With more than twenty-five years of experience in gene therapy, immunology, biochemistry and molecular biology in both industry and academic settings, he began his scientific career studying the genetic basis of bleeding disorders. At the Childrens Hospital Philadelphia (CHOP) he conducted pioneering studies on liver gene transfer with adeno-associated virus (AAV) vectors and immunology. Federico was involved in several first-inx0002human clinical studies of gene therapy based on the AAV vector platform while serving as the director of translational research at CHOPs Center for Cellular and Molecular Therapeutics. He also led studies aimed at the characterization of human immune responses to AAV vectors and the development of strategies to modulate vector immunogenicity. He then joined the French National Institute of Health and Medical Research (INSERM) as Research Director, as well as Genethon a leading French nonprofit R&D organization focused on gene therapy for rare diseases as Team Leader. There, he spearheaded the development of in vivo gene therapies for inherited diseases from bench to bedside, while continuing to focus on the characterization of human immune responses to AAV vectors and the development of strategies to overcome immune responses in gene transfer. Throughout his distinguished career, Federico has received several awards and has contributed to the field of gene therapy with more than one hundred and fifty scientific publications, including seminal findings in the field of AAV gene therapy. He is also the at-large director of the American Society of Gene and Cell Therapy (ASGCT) board of directors. Federico received his bachelors degree in biology and his Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy, and his M.B.A. from Drexel University. He also served as faculty at the Pierre and Marie Curie University in Paris, France, and Universitat Autonoma in Barcelona, Spain.

Katherine High, M.D.

Visiting Professor
Rockefeller University

Dr. Katherine High, an internist and hematologist by training, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to gene delivery vectors. Her work evolved to encompass clinical translation of genetic therapies for multiple inherited disorders, and as the Founding Director of the Center for Cellular and Molecular Therapeutics at The Childrens Hospital of Philadelphia, Dr. High assembled a multidisciplinary team of scientists and researchers working to discover new gene and cell therapies for genetic diseases and to facilitate rapid translation of preclinical discoveries into clinical application. At CHOP and Penn, Dr. High was an Investigator of the Howard Hughes Medical Institute, and held an endowed chair at the medical school. In 2013, Spark Therapeutics, a biotechnology company based in Philadelphia, was formed based on programs that Dr. High had led at Childrens Hospital and in 2014, she joined Spark full-time as President and Head of R&D in 2019, Spark was acquired by Roche. While at Spark, she led the team that achieved the first FDA approval of a gene therapy for a genetic disease in the US, for a rare form of congenital blindness, and led the development of a gene therapy for hemophilia B that has now completed Phase 3 testing. Dr. High served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past-president of the American Society of Gene & Cell Therapy (ASGCT). She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, and business certification from the UNC Business School Management Institute for Hospital Administrators. She currently serves on the Board of Directors of CRISPR Therapeutics (NASDAQ CRSP), and Incyte Corporation (NASDAQINCY), and on the Board of Trustees of the College of Physicians of Philadelphia. She is the recipient of many honors and awards, is the author of more than 200 scientific papers, and the holder of multiple issued patents on gene therapy. She is an elected member of the National Academy of Medicine (US), the American Academy of Arts and Sciences, the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (London), and the National Academy of Sciences (US). She is currently a Visiting Professor at Rockefeller University in New York.

Sheila Mikhail, J.D., M.B.A.

Co-Founder, Former Chief Executive Officer
AskBio

Sheila Mikhail has over 20 years of biopharmaceutical leadership experience and is a Co-Founder of AskBio. She served as CEO until March 2023 and currently serves as AdvisorCo-Founder. As CEO, she built three GMP manufacturing facilities in Spain and with $235m in Series A funding, built the company to over 349 employees operating in five countries. Under her leadership, AskBio advanced programs into the clinic for Pompe, late stage Heart Failure, Parkinsons, MSA, and Huntingtons. In December 2020, she led the negotiation of the $4b AskBio acquisition by Bayer AG and has since grown the company to over 800 employees. Prior to AskBio, she served as CEOCo-founder of Bamboo Therapeutics which, in 20 months, raised $50m, advanced a therapeutic for GAN into the clinic, completed pre-IND studies for a Duchenne muscular dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in a deal valued at $827m. Ms. Mikhail practiced law and founded Life Sciences Law servicing clients including Bayer, Gilead, GSK, Sanofi and Aventis. She earned a JD with honors from Northwestern University, a finance MBA with honors from the University of Chicago, and a BS with highest honors from the University of Illinois at Urbana-Champaign.

SPEAKERS

Marc Abrams, Ph.D.

Chief Scientific Officer
Carbon Biosciences

I am currently CSO of Carbon Biosciences, a venture-backed biotech company advancing novel non-AAV gene therapy vectors. Before joining Carbon in January 2023, I spent 9 years at Dicerna Pharmaceuticals, now a wholly owned subsidiary of Novo Nordisk, most recently as SVP Discovery Research. At Dicerna, I was fortunate to have led the effort to advance a new platform technology for delivery of genetic medicines, leading to multiple clinical programs and corporate partnerships. The first 17 years of my career were spent at Merck and Co, Inc. in drug discovery and early development, with a focus on both small molecules and oligonucleotide therapeutics. I am passionate about building research organizations, mentoring early-career scientists, advancing new pharmaceutical modalities, performing pioneering research in targeted delivery, and leading programs to impact underserved patient populations. I am a native of the Philadelphia area, and its great to be participating in this conference

Husain Attarwala, Ph.D.

Vice President, Head of DMPK, Clinical Pharmacology and Pharmacometrics
Aera Therapeutics

Dr. Husain Attarwala is an accomplished clinical pharmacologist, pharmacometrician and researcher in drug development for genetic medicines. He is presently the Vice President and Head of DMPK, Clinical Pharmacology and Pharmacometrics at Aera Therapeutics. Prior to this, he was serving as the Sr. Director and Head of Clinical Pharmacology and Pharmacometrics at Moderna, where his research focused on developing predictive models to aid clinical dose decisions for mRNA vaccines and therapeutics. Before that, he was a Principal Scientist at Alnylam Pharmaceuticals, where his research contributed to the selection of doses for various novel siRNA therapeutics, five of which have obtained global regulatory approval. He holds a PhD and MS in Pharmaceutical Sciences and Drug Delivery Systems from Northeastern University and a Bachelors in Pharmacy from Al-Ameen College of Pharmacy.

Lisa Berger Baskin, B.S.

Senior Vice President Head of Development
Scheer Partners

Industry veteran Lisa Berger Baskin has had an impressive 30 years of a highly diverse career in commercial real estate, including 14 years heading her own brokerage firm. During her career, she has been a licensed broker in Pennsylvania, Delaware, and California. Since joining Scheer Partners, Baskin has been a driving force behind multiple high-profile life science deals in the Philadelphia region, including BioLabs, Aro Therapeutics, Vetigentics, and Renovacors move to Princeton ahead of their purchase by Rocket. Baskin is currently finalizing the terms of an undisclosed 100,000 sf cGMP transaction and continues to provide strategic consultancy to emerging life science companies and several regional institutions on monetizing their assets. Focused on client satisfaction, Baskin has been deeply involved in a wide range of hands-on roles, such as the redevelopment of The Curtis into a life science ecosystem in Philadelphia, a newly signed 120,000 sf ground-up life science development in Newark, DE, and the redevelopment of a 100,000 sf industrial project in Philadelphia. Baskin was actively involved with the redevelopment of a project in the Inland Empire (CA) and continues to provide guidance for corporate real estate consolidations, disposition of assets, and zoning and financial analyses.

Francesco Bibbiani, M.D.

Senior Vice President, Head of Development
Dyne Therapeutics

Francesco Bibbiani MD, with over 20-year experience in clinical development, 18 years within the pharmaceutical industry with special focus on rare diseases, plus 7 additional year leading proof of concept trials at the Experimental Therapeutic Branch of the NINDS, National Institute of Health. Previously at Eisai, PTC Therapeutics, Ultragenyx and currently Head of Development at Dyne Therapeutics.

Cynthia Cai, Ph.D., M.B.A.

Venture Partner, Viva BioInnovator President
Viva BioInnovator Tharton Consulting

Dr. Cynthia Cai is an executive and investor with over twenty-five years of experience in the healthcare and life science industry. Extensive experience in equity investment, board membership, marketing, and business development. In-depth understanding of global biotech and life science business, widely recognized as having a unique ability to bridge collaboration between scientists and businesses, between the Eastern and Western worlds. Dr. Cai is the founder and president of Tharton Consulting, which provides investment and management consulting services. She is also a venture partner of Viva BioInnovator, an equity investor in biotech innovation with novel solutions to cross multiple therapeutic areas. Before that, she served as senior advisor to Northern Light Venture Capital, for its healthcare investment effort in the United States. Previously Dr. Cai had progressive leadership roles with Agilent Technologies, as global associate vice president of marketing, she was responsible for its billion-dollar Chromatography, Automation, and Mass Spec. business. Dr. Cai serves on the board of directors for Spectral MD (London SMD), Arthrosi Therapeutics, AceLink Therapeutics, Amberstone Biosciences, and Basking Biosciences. She is also a member of the board of the Science History Institute in Philadelphia. Dr. Cai earned a B.A. and M. Eng. from Tsinghua University in Beijing, received her Ph.D. in Chemistry from the University of Massachusetts, and an MBA from The Wharton Business School of the University of Pennsylvania. She had been a regular speaker at healthcare investment conferences such as BIO International Convention RESI China Focus at J.P. Morgan, SAPA Annual Conference, and Wharton China Business Forum. Dr. Cai is also a long-time career advisor for Tsinghua Global MBA and Wharton Executive MBA students.

David Chang, Ph.D.

President and Chief Technical Officer
WuXi Advanced Therapies

Dr. David Chang brings strong leadership and a wealth of experience in gene and cell therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy to WuXi ATU. He joins WuXi ATU from Celgene Corporation, a Bristol-Myers Squibb company where he was the Corporate Vice President and Head of Cell Therapy Global Manufacturing, and he had oversight of CAR-T manufacturing network and the global manufacturing sciences & technologies organizations. Prior to Celgene, Dr. David Chang was the Global Head of Engineering and Strategy at Hoffmann-La Roche based, in Basel, Switzerland, and he was previously the Vice PresidentSite Head of Roche Shanghai Technical Operations in China. Earlier in his career Dr. David Chang worked at Genentech as the Senior Director of Global Manufacturing Science and Technology, and as the Director of Process Development in its Oceanside, CA site. He was also formerly at Biogen Idec as Director of cell culture R&D, at BASF Bioresearch as a cell culture group leader, and at Schering-Plough Research Institute as a process development engineer. Dr. David Chang has a B.S. degree in Chemical Engineering from National Taiwan University, and Ph.D. and masters degree in biochemical engineering from Massachusetts Institute of Technology.

Susan Chase

Vice President, Business Development
BioLabs

Susan Chase is the Vice President Business Development for BioLabs, an internationally recognized shared laboratory and office platform for life science start-ups. Miss Chase leads the innovation consulting practice, international expansion, and development of strategic partnerships. Before devoting herself fulltime to supporting the amazing innovative companies in the BioLabs network, Susan served as the Director of Collaborative Services at MASCO, the planning organization for the Longwood Medical Area in Boston where she led contract negotiations on behalf of the hospital and academic institutions. Previous to her current work, Susan has held key operational roles directing multi-national property and facilities and risk management projects including managing aspects of the diligence process for Steward Healthcare during the Cerberus acquisition. In addition to being a strategic contributor at BioLabs and proud mother of two, Susans passion is advocating for children who have been victims of abuse and neglect and is often seen promoting the good works of nationalcasagal.org. Susan is based in the BioLabs Cambridge headquarters.



Yi-Yen Chen, Ph.D.

Associate Director
PCI Ventures, Pen Center for Innovation

Dr. Yi-Yen Chen has over 10 years of experience in the life sciences industry. She currently works at PCI Ventures, focusing on venture creation and portfolio management. Previously, she held positions at Echo Investment Capital, overseeing life sciences investments, and at Microbio Group in Taiwan, working in business development and drug licensing. At GeneTex, Dr. Chen led the development of the worlds largest antibody portfolio for zebrafish research. She completed her PhD in developmental biology at the Max-Planck Institute in Germany, under Nobel Laureate Professor Christiane Nsslein-Volhard. Her postdoctoral training includes molecular biology at the Institute of Molecular Biology in Mainz, Germany, and cancer immunotherapy at the Netherlands Cancer Institute in Amsterdam.

John Chuckalovcak, M.S.

Associate Director, dPCR Business Development
QIAGEN Inc.

Broadly trained in molecular biology and genomic analysis technologies, John Chuckalovcak has 12 years of experience supporting the implementation of digital PCR (dPCR) in the BioPharma, Applied Testing and Academic sectors. In his current role as the Associate Director of Business Development for QIAGEN, he oversees the commercial expansion efforts of the dPCR QIAcuity portfolio in North America. John earned his Bachelors degree from Indiana University and completed his Masters at the University of Virginia.

Hugh Davis, Ph.D.

Chief Operating Officer, Biosion, Inc. & President, Biosion USA, Inc
Biosion, Inc.

Dr. Davis is currently the Chief Operating Officer of Biosion Inc., a clinical stage, antibody-based therapeutic biotechnology company with sites in Nanjing, China and Newark, DE. Hugh has a 35 year career in the discovery and development of novel therapeutics at major pharmaceutical and biotechnology companies, including 20 years at Johnson & Johnson. Additionally, Hugh was the CBO of Frontage Laboratories, where he led Business Development and Sales and Marketing. Hugh was the VP and Head of the Biologics Development Sciences department in Janssen Biotherapeutics (JBIO), leading a group of up to 200 scientists in the biophysical characterization of discovery assets. In addition, over the last 5-6 years in JBIO at J&J, Hugh was also the China Biologics Leader. Together with his team, Dr. Davis was instrumental in the development and approval of many biologic therapies at J&J . Following his tenure at J&J, Dr. Davis took the role of Chief Business Officer at Frontage Laboratories, leading the company to a very successful IPO, on the Hong Kong Exchange (HKSE 1521) . Currently, Dr. Davis is the COO of Biosion, Inc. and President of Biosion USA, Inc. where he has built a team focused on the Preclinical, Regulatory, Quality, Clinical and Business Development efforts for antibody-based portfolio assets moving toward IND submission and Clinical Development. Dr. Davis holds a Ph.D. degree in Biochemistry from Villanova University and completed post-Doctoral training at Centocor, Inc. where he patented the characterization of the tumor biomarker for ovarian cancer, CA125.



Jinpian Diao-Piezunka, Ph.D., E.M.B.A.

Head of Technology Development
Spark Therapeutics

Jinpian is an Engineer who loves developing new technologies to make medicines. She studied Chemical Engineering at school with a focus on biochemical engineering. While doing her PhD, she developed a miniaturized bioreactor that can be used for highly parallel animal cell cultures. After getting her PhD, Jinpian has worked on developing and scaling-up the manufacturing processes of more than a dozen of biologics. She played a major role in the process development and global filing of Opdivo and Sarclisa. Over her 17 years of working on developing industrial manufacturing processes for medicines, she has taken on increasing responsibilities of leading teams of downstream development, integrated CMC project management, upstream development, end-to-end process development, and technical transfer, production support, and data analytics across global manufacturing networks at Genentech, Bristol Myers Squibb, and Sanofi. She joined Spark Therapeutics in 2021 as Spark's technical development head. In this role, she is helping advance gene therapy manufacturing technologies to deliver gene therapies to many more patients at lower cost. Jinpian received her bachelors and masters

degree in Chemical Engineering from Tsinghua University. She then obtained her PhD in Chemical Engineering from Cornell University. She also has an EMBA degree from INSEAD in France.

Robert Dickey, M.B.A.

Managing Director
Foresite Advisors

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in both private and publicly-traded life sciences and medical device companies. Mr. Dickey is experienced in all stages of the corporate lifecycle, including start-up and early fundraising, going public, high growth, turnarounds and exit strategies. Earlier in his career, Mr. Dickey spent 18 years in investment banking, mostly at Lehman Brothers, with a background split between M&A and capital markets transactions. His expertise includes public and private financings, M&A, partneringlicensing transactions, project management, overseeing companys finance and accounting functions, as well as interactions with Boards, VCs, shareholders and Wall Street. He is currently a Managing Director at Foresite Advisors which provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis and transactional support for fundraising and M&A. Mr. Dickey is also part of the Leadership Team at Cell One Partners, which provides consulting for cell and gene therapy companies. He currently serves as a member of the Board of Directors at AngioGenex, SFA Therapeutics and GSNO Therapeutics. Mr. Dickey holds an MBA from The Wharton School, University of Pennsylvania, and an AB from Princeton University.

Yiyu Dong, Ph.D.

Associate Director
WuXi Advanced Therapies

Yiyu Dong is Associate Director at WuXi Advanced Therapies. He has twenty years of dedicated experience in viral vector and cell line development. At WuXi ATU, he specializes in leading and developing high producing single clonal cell line and scalable lenti and AAV suspension platforms. His prime objective is to develop robust and cost-effective viral vector production process for clinical and commercial manufacturing. Prior to WuXi ATU, Yiyu Dong held positions in industry and academia with a focus on discovering and developing new platforms and targets for human diseases. He conducted translational medicine study at Memorial Sloan Kettering Cancer Center and published 30 peer-reviewed papers. Yiyu Dong holds a PhD from a joint program between Peking University and Yale University

Chaohong Fan, M.D., Ph.D.

Team Leader of Oncology Branch
DCEO, OTP of CBER, FDA

Dr. Fan is a lead oncology medical officer with 18 years of experience at the Center of Biologics Evaluation and Research (CBER) and the Center of Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA). Dr. Fan serves as a team leader at the oncology division and acted as a branch chief at the Malignant Hematology Branch at the Office of Therapeutic Products (OTP), CBER. OTAT facilitates the development and approval of cellular and gene therapeutic products with curative potential for cancer and rare diseases. Dr. Fan is an internist, hematologist, and medical oncologist certified by the American Board of Internal Medicine (ABIM). She received an M.D. from Zunyi Medical College, and a M.Sc. in medical genetics from Hunan Medical University, China. She also holds a Ph.D. in medical genetics from Umea University in Sweden. Prior to joining the FDA, Dr. Fan conducted researches in gene mapping and cloning for neurogenetic disorders, including Amyotrophic Lateral Sclerosis (ALS), at Northwestern University in Chicago, USA. Her regulatory expertise focuses on clinical trial design and development of cellular and gene therapies in oncology.

Joseph A. Fraietta, Ph.D.

Assistant Professor and Director
University of Pennsylvania

Dr. Joseph Fraietta is a devoted researcher and Principal Investigator at the Center for Cellular Immunotherapies, where he applies his expertise in Microbiology and Immunology to make a difference in the field of cancer treatment. His journey began under the guidance of Dr. Carl June at the University of Pennsylvania, where he contributed to the research that led to the FDA's approval of the first CAR T cell therapy. Today, he directs his energy towards understanding patient responses to cell-based immunotherapies, aspiring to enhance therapeutic

outcomes. His efforts have led to the identification of key biomarkers associated with CAR T cell therapy responses and he played a part in the trailblazing clinical trial of CRISPR/Cas9-engineered T cells. As a faculty member at the Perelman School of Medicine, his research findings are shared through respected scientific journals. Honored with the 2019 National Clinical Research Award, Dr. Fraietta recently had the opportunity to speak to the US Congress about the crucial importance of translational research and continuous funding.

Brahm Goldstein, M.D., M.C.R.

VP, Research & Development, Hematology
CSL Behring

Brahm Goldstein, MD, MCR is the Vice President, Research and Development, Hematology at CSL Behring. Brahm has an M.D. degree from SUNY Health Science Center and a Masters in Clinical Research from Oregon Health & Science University. He has held leadership roles in the biotechnology and pharmaceutical industry for the past 17 years at several companies including Novo Nordisk, Ikaria, Baxter, Shire, and Global Blood Therapeutics. Prior to transitioning to the pharmaceutical industry, Brahm was in academic medicine for over 25 years as a pediatric critical care physician with positions at Massachusetts General Hospital/Harvard Medical School, University of Rochester School of Medicine and Dentistry, and Oregon Health & Sciences University.

Stephen Gacheru, Ph.D.

Vice President, Biologics, Gene & Cell Therapy Operations (BGC)
Frontage Laboratories, Inc

Stephen is an executive leader with a passion for exploring and applying science to develop unmet medical therapies based on Biologics, Gene, and Cell Therapy platform. Stephen graduated from Boston University, Chemistry department in 1989 with a Ph.D. in Chemistry followed by postdoctoral training at Roche Institute of Molecular Biology in Nutley, NJ. Stephen has over 20 years' experience working with major pharmaceutical companies and has developed experience in managing high performing technical teams. Stephen has experience in process development and analytical technology for innovative drugs. Stephen has experience in leading operations and CMC teams responsible for development, manufacturing, and supply of clinical and commercial biological therapeutic products. Ensuring coordination, seamless communication, and execution across different departments and functions by building and nurturing close, trusting relationships, frequent interaction, and oversight of key deliverables. Stephen has taken increasing leadership roles in process and analytical development during drug development process with global experience in management and oversight of external manufacturers and construction of manufacturing and quality control facilities. Stephen has built Gene and Cell Therapy laboratories and implemented technologies to support method development and GMP Release and Stability testing.

Tom Gordon, M.B.A.

Managing Director
Silicon Valley Bank

Tom Gordon is a Managing Director for Silicon Valley Bank, a member of SVB Financial Group. Tom leads a dedicated team of professionals in the Philadelphia office serving the Life Science, Technology and Clean Tech markets in Pennsylvania and New Jersey. The Philadelphia team also works closely with the venture capital and private equity firms that invest in these sectors. Tom joined SVB Financial in 2004. Prior to SVB, Tom worked in Middle Market Corporate Banking and Specialty Finance at PNC Bank and Bank of America. Tom is active in many of the organizations that support the entrepreneurial communities in Pennsylvania and New Jersey, including the MAC Alliance, Pennsylvania Bio, New Jersey Bio, The New Jersey Technology Council and the Pittsburgh Venture Capital Association. Tom holds a degree in Finance from the Pennsylvania State University and also holds an MBA from St. Josephs University.

Rebecca Guzman, J.D.

Partner and Vice Chair of M&A Division
Duane Morris LLP

Rebecca Guzman is a corporate transactional partner at Duane Morris. She focuses on the representation of start-up and emerging growth companies with a focus on life science companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries. Her practice spans the entire corporate lifecycle, from formation through liquidity. In addition to her company

client counsel, Rebecca represents a number of prominent venture capital funds and institutional investors in their financing activities. Rebecca is broadly experienced in M&A and currently serves as a vice chair of the M&A Division of the firm. Resident in Duane Morris Delaware office, she also has extensive experience and regularly advises in all areas of Delaware corporate and alternative entity law. Rebecca was named to Best of the Bar by the Philadelphia Business Journal in 2022 and recently named a Most Effective Deal Maker by the Legal Intelligencer.

Jianming Jimmy Hao, J.D., Ph.D., M.B.A.

Partner, Chair of Patent Practice, Co-Chair of Pharma & Biotech practice
Fox Rothschild LLP

Mr. Hao is a Partner, Chair of the Patent Practice, and Co-Chair of the Pharma & Biotech practice at Fox Rothschild LLP. With decades of legal experience, Mr. Hao serves clients including Fortune 500 companies, startups, entrepreneurs, investors, and academic institutions on a broad range of legal issues, including patent, trademark, licensing, IP litigations, international, corporate, vc financing, and nonprofit. While focusing on preparation/prosecution of U.S. and foreign patents. He provides a full range of patent law services, including developing and managing worldwide patent portfolios, assisting in patent matters in connection with startups, strategic alliance, technology transfer, corporate transactions, freedom-to-operate, invalidity and non-infringement opinion analysis. Mr. Hao has provided representation to several notable business transactions, including Alexion Pharmaceuticals Inc.'s acquisition of Synageva BioPharma, Humanwell Pharmaceutical Group Corporation's acquisition of Epic Pharma, BMS's acquisition of Amira Pharmaceuticals, licensing and collaboration deals involving major universities and companies. Mr. Hao received a J.D. from Boston College Law School, a PhD from Columbia University, an MBA from Cornell University, and a BS from Nankai University. He is a co-founder of BioKatalyst, a non-profit organization of Chinese business leaders in commercial areas of biopharmaceutical industry.

Amanda Hays, Ph.D.

Scientific Officer (Senior Director)
BioAgilytix Labs

Amanda Hays is a Scientific Officer and Senior Director at BioAgilytix Laboratories. She offers more than a decade of lab experience in multiple fields, including pharmacology, drug metabolism, immunoassays, immunogenicity, biomarkers, flow cytometry and qPCR and has supported programs through all stages in drug development. In her current role, she provides global scientific leadership and technical guidance. Dr. Hays is the Chair of the AAPS Biomarkers and Precision Medicine community and the AAPS qPCR working group. She earned her Ph.D. in Pharmacology from the University of Kansas Medical Center.

Kevin He, B.S., M.B.A.

Director of Business Operations
uBriGene Biosciences

Kevin is a Director of Business Operations at uBriGene Biosciences, a global CDMO for cell and gene therapy. Kevin brings over 15 years of sales and marketing experience in the financial, industry gas, and biotech industries. He specializes in collaborating with executive teams on strategy development and in solving complex business problems. He has a proven track record of increasing the sales pipeline and contributing to the companys top and bottom-line growth. Kevin grew up in Philadelphia and earned a bachelors degree and an MBA from Penn State University at University Park, PA. Kevin is a very active volunteer in the Philadelphia community. Currently, he serves as the Chief Operating Officer at the National Association of Asian American Professionals (NAAAP) Philadelphia Chapter, where its mission is to provide a professional development platform for the Asian American professionals and to serve the local Asian community. He is passionate about diversity and inclusion, he has founded and chaired an Employee Resource Group (ERG) for Asian American employees while at Air Products. He has also co-founded a mentoring program for a local elementary school in2009, and still an active mentor.

Jie He, M.S.

Lead Consumer Safety Officer
FDA/CBER/Office of Compliance and Biologics Quality/Division of Manufacturing and Product Quality

Mr. He joined FDA/CBER in the Office of Blood Research and Review (OBRR) as a Regulatory Project Manager in 2008 and then in the CBER Office of Compliance and Biologics Quality (OCBQ), Division of Manufacturing and

Product Quality as a CMC Reviewer/Inspector in 2011. As a Team Lead, Mr. He provides general oversight for CMC (facility, equipment, and manufacturing process) reviews and inspections in the Manufacturing Review Branch for CBER regulated products including biologics, vaccines, recombinant proteins, in vitro diagnostics, devices, allergenic, blood components, and gene/cell therapy products.



Xianxin Hua, Ph.D., M.D.

Professor
University of Pennsylvania

Xianxin Hua, M.D., Ph.D., Professor of Cancer Biology, Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine. Dr. Hua has a long-term interest in investigating how the Menin epigenetic pathway regulates gastrointestinal (GI) cancers including neuroendocrine tumors (NETs) as well as acute myeloid leukemia (AML), and in developing innovative chimeric antigen receptor (CAR)-expressing T cell therapies. Although CAR-T therapy has achieved remarkable success in treating B cell lineage-related leukemia, the progress is lagging for treating solid cancers. Dr. Hua's team invented the STAR technology platform to quickly identify multiple antibodies targeting tumor associating antigens (TAAs) for solid cancers. His group developed novel CAR T therapy for treating the aggressive GI-cancers, and recently discovered that CDH17CART cells eradicated multi-types of solid cancers, including NETs, gastric and colorectal cancers, and pancreatic cancers in preclinical models. Notably, CDH17CARTs do not cause toxicity to healthy normal cells that also express CDH17 protein. These studies pave the way to develop novel immunotherapy to treat the aggressive solid cancers. Dr. Hua's research led to multiple patents including CDH17CART technology licensed to Chimeric Therapeutics by Penn. He has also involved in startups and consulting for biotech companies, and published over 100 peer-reviewed papers in journals including Nature, Cell, and Nature Cancer.

Yuxiang Huang, Ph.D.

Senior Director
WuXi Advanced Therapies

Yuxiang Huang, PhD, is a senior director of cell therapy PD at WuXi Advanced Therapies at Philadelphia, PA. His work focuses on process development and technology development of cell therapy technologies, including CAR-T, TIL, TCR-T, NK and stem cell therapies.

Vasant Jadhav, Ph.D.

Senior Vice President
RNAi Platform
Alnylam Pharmaceuticals

Vasant Jadhav is a Senior Vice President of Research at Alnylam Pharmaceuticals, where he leads the Alnylam Technology group responsible for siRNA designs, new applications and delivery solutions that have led to 5 approved drugs and deep pipeline across multiple tissue targets. Prior to Alnylam, Vasant was at SirnaMerck for 12 years and worked on optimizing siRNA chemical modifications and leading the efforts on conjugate delivery approach. He obtained his PhD in Biotechnology from the University of Pune in 1998 and post-doctoral fellowship at University of Colorado, Boulder working on ribozymes. Dr. Jadhav has authored 30 peer-reviewed publication in the field of nucleic acids therapeutics.

Danuta Jarocha, Ph.D.

Senior Research Investigator
University of Pennsylvania

Dr. Danuta Jarocha graduated from Jagiellonian University, Medical College with a degree in Medical Analytics, followed by a Ph.D. in Medical Biology. Her graduate work combined hematopoietic stem cell transplantation-related clinical work with academic research. Dr. Jarochas post-doctoral work enabled multiple, human mesenchymal stem cells based, successful, medical experiments and clinical trials in Poland. In 2014, Dr. Jarocha came to the USA to Dr. Ponczs lab at CHOP to explore the possibilities of using induced pluripotent stem cells as a source to produce donorindependent platelets. Next two years she worked in a gene therapy group with Dr. Rivella. She successfully combined advanced cell culture methodology with the newest molecular techniques including digital PCR and deep sequencing to develop new assays to perform ALS20 -globin clinical vector analysis including percentage of full transcript containing lentiviral particles, viral transcriptome sequence identity and transducibility of CD34 clonogenic progenitors. Her next step, CRO-based industry experience, built a deep understanding of new assay validation processes. In 2022, Dr. Jarocha joined the

TSCL as Senior Research Investigator to support molecular assay development and molecular group operation. Her high-impact findings have been published in Blood, Blood Advances, Hematologica, Transfusion, Stem Cells Translational Medicine, Cell Transplantation, and others.

Ohnmar Khanal, Ph.D.

Process Development Downstream Technology Lead
Spark Therapeutics

Ohnmar Khanal is a Process Development Downstream Technology Lead at Sparks Therapeutics. Ohnmar received a BS in Chemical Engineering from MIT and a Ph.D. in Chemical Engineering from the University of Delaware. Her interest and expertise lie in designing novel separation strategies for various drug modalities, employing experimental and model-based approaches. Her previous work addresses biomacromolecules retention, adsorption, competitive binding, and transport in depth filtration and chromatography. She has developed novel methodologies and techniques using her fundamental understanding of protein transport and biophysics.

Roland Kolbeck, Ph.D.

Chief Scientific Officer
Spirovant Sciences

Dr. Roland Kolbeck is Chief Scientific Officer of Spirovant and is responsible for leading the companys research efforts. He delivers more than 20 years of research and executive leadership experience, specializing in respiratory and autoimmune sciences. Previously Dr. Kolbeck held executive roles of increasing responsibility and leadership at MedImmune, AstraZenecas global biologics organization. Most recently, he served as Vice President, Head of Respiratory, Inflammation and Autoimmune research (RIA) and a member of the MedImmune Research Leadership Team as well as the Early Stage Portfolio Committee. During his tenure there, he set the scientific vision for more than 80 scientists led the advancement of eight novel candidates into the clinic, including FASENRA, AstraZenecas first biological for the treatment of severe eosinophilic asthma and contributed to the spinout of five preclinical-stage autoimmune assets. Prior to that, he held senior scientific roles at Peptimmune and Millennium Pharmaceuticals. Dr. Kolbeck conducted his postdoctoral research in the Department of Neurobiochemistry at the Max-Planck Institute for Neurobiology, Munich. He earned a PhD from the University of Regensburg and Max-Planck Institute of Neurobiology, Munich. Dr. Kolbeck has authored more than 100 publications and is co-inventor on 6 pending or granted patents.

Karen Kozarsky, Ph.D.

Chief Scientific Officer & Founder
SwanBio Therapeutics

Karen Kozarsky, Ph.D., is Chief Scientific Officer and Co-Founder of SwanBio Therapeutics. She has 30 years of experience in gene therapy, with a primary focus on the development of gene therapy for inherited rare diseases utilizing adeno-associated virus (AAV) vectors. She has been involved in the development of multiple gene therapy products that are in clinical trials. Previously, Dr. Kozarsky was President of Vector BioPartners, VP of R&D at REGENXBIO Inc., and Head, Gene Therapy in the GlaxoSmithKline Biopharm group. Prior to that, she worked in gene therapy at the University of Pennsylvania and at the University of Michigan. Dr. Kozarsky was named by the Alliance for Regenerative Medicine as the first co-Chair of the Gene Therapy Section to support policies to advance novel gene therapies and has been a committee member for the American Society of Gene & Cell Therapy. Dr. Kozarsky received a Ph.D. in Biology from MIT and a B.A. in Biology from Amherst College.

Eric Law, M.S.

Head of CMC Regulatory Affairs
Century Therapeutics

Eric Law is the Head of CMC Regulatory Affairs at Century Therapeutics. Before joining Century, Eric has held various roles in the Global Regulatory Sciences-CMC and Cell Therapy Development organizations at Bristol Myers Squibb (BMS)/Celgene, where he spearheaded the regulatory strategy and process development efforts for a number of complex cell-based immunotherapy products through IND and clinical development stages. Eric led the successful submission of the marketing authorization application (MAA) in Europe for Abecma, the first chimeric antigen receptor T (CAR-T) cell therapy for multiple myeloma, which was subsequently approved in 2021. Eric received his B.S. and M.S. in Biochemical/Chemical Engineering from Rutgers, the State University of New Jersey.

Shiowjen Lee, Ph.D.

Deputy Director
CBER Division of Biostatistics, FDA CBER

Shiowjen Lee, PhD, has worked at FDA for over 20 years with statistical review experiences across drugs, devices, and biological human-use medical products. She is currently Deputy Director of Division of Biostatistics in the Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research at FDA that regulates vaccines, blood, tissue, cell, and gene therapy products. She has lengthy contributions to product approvals and has received numerous FDA honors and awards. She has recently been involving in Covid-19 pandemic response, the milestone of 2017's three gene therapy products approval including two CAR-T therapies for leukemia and lymphoma and gene-replacement therapy for childhood vision loss, and numerous FDA policy developments such as biomarker and demonstrating substantial evidence of effectiveness for product approval. Her statistical interests span a range of topics, has currently been focusing on statistical issues related to gene therapy product development for rare diseases and the use of real-world data and evidence for regulatory decision making. She received her doctorate in Statistics from University of South Carolina.

Dongfang Liu, Ph.D.

Associate Professor (Tenured)
Rutgers University

Dongfang Liu, Ph.D., an Associate Professor (tenured) and Director of the Immunoassay Development Program at the Department of Pathology, Immunology and Laboratory Medicine at Rutgers University- New Jersey Medical School. In 2012, Dr. Liu was recruited to Baylor College of Medicine as a tenure-track Assistant Professor in the Department of Pediatrics, and Pathology & Immunology, before joining Houston Methodist Research Institute (HMRI) as an Assistant Professor in 2015. In 2018, Dr. Liu was promoted to Associate Professor at HMRI. Dr. Liu did his Ph.D. and postdoctoral training on natural killer (NK) cells. After completing the postdoctoral training, he joined the Ragon Institute of MGH, MIT and Harvard in 2011 as a senior research scientist, working on HIV-specific immune cell dysfunction. Dr. Lius current research primarily focuses on the immunobiology of NK, immunological synapse and chimeric antigen receptor (CAR)-NK cells. He has more than 20 years of experience in NK cell research. Dr. Liu has published research papers in top-tier journals, including Nature Immunology, Immunity, Nature Communications, JACI, Proc. Natl. Acad. Sci., and others. Dr. Liu serves on several editorial boards for multiple journals and as a reviewer for a number of journals and several grant agencies.

Zhiping Liu, J.D., M.B.A.

Founder
Liu Chen & Hoffman LLP

Mr. Liu specializes in corporate law and focuses on corporate governance, mergers and acquisitions, commercial loans, joint ventures, hedge fund and private equity fund formations and commercial agreements. Prior to establishing Liu, Chen & Hoffman LLP, Mr. Liu practiced in prestigious Wall Street and Silicon Valley law firms for more than seven years, where he advised various clients in completing more than 100 corporate transactions totaling more than $7 billion in value. Mr Liu received his JD from NYU Law School.

Leyuan Ma, Ph.D.

Assistant Professor
Childrens Hospital of Philadelphia (CHOP), University of Pennsylvania

Dr. Ma obtained his PhD degree in biomedical sciences from Dr. Michael Greens lab at the University of Massachusetts Medical School in 2016. Following graduation, Dr. Ma continued his postdoctoral fellowship in Immunotherapy and Immune Engineering at Massachusetts Institute of Technology and Howard Hughes Medical Institute under the guidance of Dr. Darrell Irvine. During his fellowship, Dr. Ma developed a synthetic booster vaccine to enhance the Chimeric Antigen Receptor T cell therapy for solid tumors, and he was supported by American Cancer Society postdoctoral fellowship from 2019-2021. In 2022, Dr. Ma was appointed as an assistant professor in the department of Pathology and Laboratory Medicine at the University of Pennsylvania. Dr. Ma is also a member of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics (CCMT) at the Childrens Hospital of Philadelphia. Dr. Ma was awarded the NIAID new innovators award (DP2).

Jolly Mazumdar, Ph.D., M.B.A.

Co-Founder and former chief executive officer
Chimeron Bio

Jolly Mazumdar, PhD, MBA, is a Biotech Entrepreneur with 13 years of drug discovery and development experience spanning big pharma and biotech. Jolly co-founded Chimeron Bio, a leading-edge RNA biotech based in Philadelphia, PA, and was the Companys President, Board Member and CEO from 2017-2022. Under her leadership, Chimeron developed a novel self-amplifying RNA technology platform for applications in Oncology, Infectious Diseases and Rare Gene Disorders. She built the foundational team and infrastructure and successfully transitioned the Company to its new management upon securing additional investment to enable the next phase of the Company growth- product development and advancement to the clinic. Previously, Jolly was the clinical biomarker lead for Oncology at GSK where she was part of the clinical development leadership team to win accelerated approvals for targeted melanoma drugs Tafinlar and Mekinist, and Blenrep, the first antibody-drug conjugate targeting BCMA therapy for multiple myeloma. Her experience spans Phase-1 through post-marketing studies for small molecules, biologics and epigenetic modifiers. She also has experience with Companion Diagnostics. Jolly conducted her post-doctoral training at the University of Pennsylvania after completing her Ph.D. at the University of Georgia. She holds an M.B.A. from the Columbia Business School. She is deeply passionate about new technology development for smart medicines, the Philadelphia life science ecosystem and advancing women in science and entrepreneurship.

Marian Nakada, Ph.D.

Vice President of Venture Investments
Johnson & Johnson Innovation-JJDC

Marian Nakada, VP Venture Investments for Johnson & Johnson Innovation JJDC, has over 30 years of experience in the pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocors acquisition by Johnson & Johnson. She transitioned to Janssen Business Development and joined JJDC, Johnson & Johnsons corporate venture group in 2013. She is passionate about leveraging Johnson & Johnsons capabilities to help her portfolio companies succeed. Marian has a A.B. in Biology from Harvard College and a Ph.D. in Pharmacology from the University of Pennsylvania. She has authored 62 peer reviewed publications and 14 book chapters and is a past reviewer for the NIH Pharmacology Study Section. She is currently on the Boards of Redona Therapeutics, Navitor Pharmaceuticals, and a stealth NewCo as well as the New England Venture Capital Association where she is working to champion change as an active contributor to its diversity & inclusion efforts. Outside work, Marian is a Board Member at InnerCity Weightlifting whose mission is to amplify the voice and agency of people who have been most impacted by systemic racism and mass incarceration.

Snehal Nalik, Ph.D.

Head of Regulatory Policy, Strategy Leader
Spark Therapeutics, Inc.

Snehal brings a confluence of regulatory affairs, early discovery, innovation, policy, and scientific expertise to her current hybrid role as Spark's Head of Regulatory Policy and Intelligence, and Regulatory Strategy Leader for ocular programs. In this capacity she established the regulatory policy function at Spark and is supporting global development of gene therapies. In keeping with her keen interest in influencing gene therapy policy and shaping the regulatory framework for advanced therapies, Snehal co-chairs the regenerative medicine committee at BIO and staffs the regulatory affairs committees of the American Society of Gene & Cell Therapy and the Bespoke Gene Therapy Consortium, along with efforts at the Alliance for Regenerative Medicine and the Innovative Medicines Initiative. With a penchant for exploring the unexplored, she has led biology programs at both Pfizer's Centers for Therapeutic Innovation and Johnson & Johnson's Janssen Incubator, and founded and led a cross-functional gene therapy community of practice at JnJ. Snehal graduated summa cum laude with an AB-MA in Biology from Bryn Mawr College, and holds a Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis where she also completed the Cancer Biology pathway with the Siteman Cancer Center.

Anh Nguyen, M.D., M.B.A.

Vice President, Sector Leader
Asklepios Biopharmaceutical (AskBio)

Anh Nguyen, MD, MBA, is a clinician-scientist and a Vice President, Therapeutic Sector Lead at Asklepios BioPharmaceutical (AskBio), who develops in vivo gene therapies for rare disease. Previously, Nguyen served as a medical officer for both the US Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS). He began his industry career as a global medical director developing biologics and combination products at Baxter. Nguyen is a Kauffman Fellow, FDA Commissioners Fellow, and a Robert Wood Johnson Foundation Health Policy Fellow. During his RWJF fellowship on the US Senate Committee on Health, Education, Labor and Pensions he helped draft legislative policies as part of the 21st Century Cures Act - enacted into law in 2016. Nguyen regularly volunteers as active senior medical staff at the NIH and is a recipient of the NIH Directors Award. Nguyen received a combined BS-MD degree from the New Jersey Medical School, and an MBA from the University of Chicago Booth School of Business. He completed both his residency in anesthesiology and a fellowship in adult and pediatric cardiovascular anesthesiology at the Massachusetts General Hospital - Harvard Medical School.

Leo Ou, Ph.D.

Vice President
Genemagic Biosciences

Dr. Li Ou is currently the Vice President at Genemagic Bio, a startup focused on AAV gene therapy for neurological and ocular diseases. Previously, Li was Associate Director of Gene Therapy at Capsida Biotherapeutics and Assistant Professor at the University of Minnesota, USA. Li obtains his PhD in Genetics (minor in Biostatistics) at the University of Minnesota. He has over 10 years of experience in leading IND-enabling studies of gene therapy (AAV, lentivirus, ZFN, CRISPR, gene regulation), resulting in 2 IND approvals, 6 pending patents, 26 manuscripts, 63 abstracts, and 23 oral presentations.

Pan Pan, Ph.D., M.B.A.

Director of Business Development
Akeso Inc.

Dr. Pan Pan has over 10 years of experience in Strategic Planning, Business Development & Licensing, Alliance Management, and Drug Development. He has been focused on collaborative development, strategic partnering and licensing transactions for innovative biological drugs in oncology and immunology. Dr. Pan has served as the group lead of Business Development at Akeso Biopharam, KLUS Pharma, and several other small to mid-cap biotech companies, with a track record of executing partnerships with record-high values, including a $1.4B license to Merck & Co. and a $5B license to Summit Therapeutics. Prior to his Business Development career, Dr. Pan led protein engineering at Arkema Inc and received several patent grants. Dr. Pan received his PhD in Chemistry from Stony Brook University and an MBA from University of Massachusetts Amherst.

Wendy Pan, J.D., Ph.D.

Partner
Goodwin Procter LLP

WENSENG "WENDY" PAN, JD & PhD, is a partner of Goodwin Procter, a leading internal law firm with top notch life sciences practices. She has advised biotech and pharmaceutical companies at all stages, addressing a broad spectrum of legal needs, from initial company formation, corporate governance, to growth stage financing, partnership and joint venture, to IPO. She has represented buyers, sellers, private equity and venture capital investors in mergers and acquisitions, stock and assets acquisitions/divestures, control acquisition, minority investments, going private, de-SPAC transactions. She has handled numerous strategic licensing and partnership deals between global pharmaceutical companies and biotech companies, involving small molecule, biologics, gene therapies, cell therapies, medical devices, diagnostic products. Apart from transactional practice, she also helps her clients in resolving contractual disputes in complicated life sciences partnership arrangements. Her deep legal experiences, coupled with her unparalleled understanding about the businesses and technologies and her pragmatic approach have won recognitions by IFLR1000 as a leading lawyer for M&A, Who's Who Legal: Life Sciences (Transactional).

Wendy obtained her JD from Columbia University School of Law and a PhD in chemistry, also from Columbia. She is also a registered US patent attorney.

Parimal Pande, Ph.D.

Associate Scientific director
Johnson & Johnson

Dr. Pande is a scientist with a wide breadth of experience in the field of toxicology and molecular genetics. He has obtained Ph.D. from the University of Connecticut USA and masters degree from the University of Houston Clear-Lake. He is currently working as Associate Scientific director at Janssen Pharmaceuticals USA in the genetic toxicology department. At Janssen, he is actively involved in developing strategy to assess the off-target effects and insertional mutagenesis of the lentivirus and CRISPR therapeutics. Previously, he had worked at the Boehringer Ingelheim Pharmaceuticals for 10 years in the investigative toxicology department, where he supported biomarkers and toxicogenomic assessments of the preclinical phase I enabling studies. He has also supported the safety strategy of AAV based therapeutics. Dr. Pande has over 15 years of experience in the field of toxicology and developed expertise in the field of molecular genetics. He is actively involved in the external consortiums like HESI CT-TRACs where hes currently leading a workstream to answer questions related to genomic stability in the allogeneic iPSC derived CAR-T therapeutics.

Adam Pfendt, M.ChE

Senior Director, Process Development
Carisma Therapeutics

Adam is currently Senior Director of Process Development at Carisma Therapeutics, overseeing teams developing viral vector and cell product platforms producing a novel first in human CAR macrophage therapeutic for treatment of solid tumors. With over 14 years of industry experience, he serves as a technical subject matter expert responsible for authoring regulatory documents and collaborating with internal and external manufacturing, process, and analytical partners to drive key CMC initiatives. He previously worked as Associate Director of PD at WuXi Advanced Therapies as the upstream PD head and CMC team lead, leading technical evaluations of new projects across cell therapy, gene therapy, and viral vector modalities for contract manufacturing and development. His career started in PD at Merck Sharp & Dohme supporting Keytruda global CMC upstream technology transfer and regulatory filings and development of Rotateq live viral vaccine process and potency assay optimization initiatives. He was raised in Kentucky and has bachelors and masters degrees in chemical engineering from the J.B. Speed School of Engineering at the University of Louisville.

Bryan Poltilove, M.B.A.

Operating Partner
BroadOak Capital Partners

As Operating Partner, Mr. Poltilove leads BroadOaks investment strategy in Cell and Gene Therapy, Bioproduction, and Cell Biology. Mr. Poltilove joined BroadOak after 12 years with Thermo Fisher Scientific where he served as Vice President and General Manager. Mr. Poltilove led long-range strategy and day-to-day operations for the companys cell and gene therapy business. Prior to Thermo Fisher, Mr. Poltilove served as Director of Revenue Strategy & Operations at the Corporate Executive Board and also held several commercial strategy roles with Johnson & Johnson. He holds Bachelors degrees in Chemical Engineering and Economics from the Massachusetts Institute of Technology as well as an MBA from the J.L. Kellogg School of Management at Northwestern University.

Leo Qian, Ph.D.

Co-founder and Vice President, Discovery Research
Entrada Therapeutics

Ziqing Leo Qian, Ph.D. is co-founder and Vice President, Discovery Research at Entrada Therapeutics, a Boston-based biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular therapeutics. Dr. Qian co-invented Entradas Endosomal Escape Vehicle (EEV) platform, which is applied to the design and development of intracellular delivery of biological cargos, including oligonucleotides, proteins, and peptides. Leo obtained his Ph.D. in Organic Chemistry from The Ohio State University.

Matthew Reber, M.S., M.B.A.

Partner
1315 Capital

Matthew joined 1315 Capital as Partner in 2017, bringing extensive healthcare investing experience across debt and equity transactions. Prior to joining 1315 Capital, he spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director. He currently serves on the board of ProSciento and Restorative Therapies, and previously served on the board of Reaction Biology (acquired by Cobepa) and Verogen (acquired by QIAGEN). Matthew also serves on the Board of Directors of Life Sciences Pennsylvania. Matthew has over a decade of growth stage investing experience with a focus on the specialty pharmaceutical and medical technology sectors. Prior to HealthCare Royalty Partners, Matthew worked at Accretive LLC and Paul Capital Partners. Earlier in his career, he worked as a principal investor focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co. Matthew started his career as a healthcare investment banker at Morgan Stanley. Matthew has worked on over $1 billion in healthcare financings over the course of his career. Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania.

Mark Rolfing, M.S.

Vice President of Operations
Almac Clinical Services

Mark Rohlfing is Vice President of Operations at Almac Clinical Services in Souderton, PA, leading day-to-day site operations in clinical supply chain management, project services, manufacturing, packaging, and global logistics. As a member of the executive team, he works closely with Almacs entire global service organization to ensure superlative collaboration and optimal process development and control to meet and exceed customer standards. Mark was previously Director of Quality at Almac and has 25 years of professional experience within GMPGCP Operations, QAQC, and Regulatory Compliance including positions at Almac, Cell Pathways Inc., and Teva Pharmaceuticals USA. He holds a Bachelor of Science degree in Biology from Millersville University of Pennsylvania and earned his Master of Science degree in Biology from Villanova University. He is an ASQ Certified Manager of QualityOrganizational Excellence, ASQ Certified Quality Auditor, and ASQ Certified Six Sigma Green Belt. He is also a Senior Member of the American Society for Quality and a member of the Parenteral Drug Association.

Niranjan Y.Sardesai, Ph.D., M.B.A..

Founder, President & CEO
Geneos Therapeutics

Dr. Sardesai founded Geneos Therapeutics, a clinical stage biopharmaceutical company focused on personalized immunotherapies for cancer and serves as its President & CEO. The company's treatments identify specific genomic changes in the cancer cells of each patient relative to their own normal cells and train the patient's own immune system to kill their cancer cells. Previously he served as Chief Operating Officer and Head of R&D at Inovio Pharmaceuticals where he led the development of Inovio's DNA Medicines platform and pipeline. His expertise spans broad aspects of biopharmaceutical development particularly as related to infectious disease vaccines and cancer immunotherapies. Dr. Sardesai received his PhD in Chemistry from the California Institute of Technology and MBA from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Mumbai. Dr. Sardesai has authored over 120 peer-reviewed manuscripts and has been granted multiple patents. He was recognized by PharmaVoice magazine as one of the top 100 most influential and inspirational leaders across the life sciences industry (2015). He lives in Blue Bell, PA with his wife and their two sons they are raising to be responsible global citizens.

Kathleen M. Shay, J.D.

Partner
Duane Morris LLP

Kathleen M. (Kate) Shay, a partner at the law firm of Duane Morris LLP, is a corporate, transactional and finance lawyer who represents both established and emerg-

ing businesses in a wide range of transactions and legal issues, including equity and debt financings, collaboration and corporate partnering transactions, licenses and other strategic relationships, mergers and acquisitions, governance matters, and executive employment and compensation issues. Kate serves on the Boards of Directors of University City Science Center, Life Sciences PA, Penn State Research Foundation and the Board of Consultors of Villanova Law School, and is a Director Emeritus of the Philadelphia Alliance for Capital and Technologies and a Trustee Emeritus of the Academy of Notre Dame de Namur. Kate previously served as a director of the Philadelphia Chapter of the Association for Corporate Growth and as the Chair of the Executive Committee of the Business Law Section of the Philadelphia Bar Association and is a past-Chair of the Securities Regulation Committee. Kate received her B.A. from Villanova University and her J.D. from Villanova University School of Law, where she served as Editor-in-Chief of The Villanova Law Review.

Andreas Solomos, Ph.D.

Director
WuXi Advanced Therapies

Dr. Solomos research focus and training has been based in CNS immunity and viral pathogenesis. He completed his doctorate at Drexel College of Medicine in Microbiology and Immunology. His postdoctoral training at Trinity College Dublin focused on cancer immunology collaborating with industry. Dr. Solomos currently leads the Virology Operations group at WuXi Advanced Therapies performing safety and regulatory testing on biologic drug products and cell and gene therapy vectors.

Kate Sullivan, M.S.

Vice President of Business Investment and Regional Marketing
The Chamber of Commerce for Greater Philadelphia

Kate Sullivan is the Vice President, Business Investment and Regional Marketing for the Chamber of Commerce for Greater Philadelphia, where she leads a team that works to attract businesses and talent to work and do business in the Greater Philadelphia region. Kate has been with the Chamber since January of 2023. Prior to joining the Chamber, Kate was the Deputy Director, Strategic Partnerships at Philadelphia International Airport. There, she led the growth functions for Philadelphia International Airports Revenue team, including marketing and branding, air service development and cargo services, guest experience and innovation.

Xiulian Sun, Ph.D.

Founder and Chief Technical Officer
uBriGene Biosciences Inc.

Dr. Sun is the Founder and Chief Technical Officer at uBriGene Biosciences Inc. She is a seasoned healthcare executive with over 10 years of experience in the commercialization of viral vectors, research, drug development, and manufacturing. As the founder, she led the technical team to build GMP systems including GMP-compliant vectors construction for gene therapy, manufacturing and purification technology, cell line establishment and screening technology, etc. She also led the development of CAR-T technology, especially ICAR30 T cells for Hodgkin lymphoma, and filed an international patent application under the PCT to obtain independent protection of intellectual property. Previously, as co-founder and chief scientist of Vigene Biosciences Inc., Dr. Sun oversaw the commercialization of human gene banks and virus packaging platforms. Dr. Sun studied and worked at The School of Medicine, Nankai University, Institute of Hematology and Blood Diseases, Chinese Academy of Sciences and holds a PhD from the University of British Columbia (UBC), Faculty of Medicine. She is the recipient of the prestigious title of First Distinguished Taishan Scholar, for her contribution to scientific and technological innovations. She is the only member in Greater China amongst 14 members of USP AAV Expert Panel.

Leon 'Jun' Tang, Ph.D., M.S.

Founding Partner
InScienceWeTrust BioAdvisory

Leon 'Jun' Tang, Ph.D. is the founding partner of InScienceWeTrust BioAdvisory, a consulting firm focused on the US/APAC cross-border business development in pharmaceutical industry. Dr. Tang is also a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund. Dr. Tang founded and has been managing InScienceWeTrust Community, a global Asian biotech professional community of ∼1,100 members, most of whom reside in the US or/and China. Dr. Tang is also an advisor to BioSpark Group, a Boston-based nonprofit primarily

consisting of Asian professionals in biotech and biopharma sectors around the world. Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York. Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor's degree from Tianjin University, master's degree from Nankai University, Ph.D. from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.

Mark Tang, Ph.D., M.B.A.,M.P.H.

Managing Director and Partner
Good Health Capital New York

Mark Tang is a managing director of Good Health Capital New York, a healthcare PEVC fund. A veteran Chinese biotech investment banker from mainland China, Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He was a biotech director at Rutgers Business School and a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of The Essential Biotech Investment Handbook, which is published both in English and Chinese. Mark has been a co-founder of two tech startups with exits and is currently on the boards of two US biotech companies. He holds degrees from NYU Stern and the Harvard School of Public Health.

Lou Tonon

Senior Associate
Scheer Partners

As a Senior Associate at Scheer Partners, Lou specializes in the leasing, purchasing, and selling of scientific real estate throughout the Philadelphia Metro Area. He previously completed 47 transactions totaling more than 400,000 SF and $43 million in value in 2021 at NAI Geis Realty Group. Lou is determined to provide comprehensive real estate services and solutions to landlords and tenants alike. Using both market knowledge and understanding of the fundamentals of scientific real estate, he continues to help identify potential candidates for scientific conversions for buyers and tenants. He studied International Business and Spanish at Mount St. Marys University in the Richard J. Bolte, Sr. School of Business.

Venkata Vepachedu, Ph.D.

Associate Scientific Director (Molecular Biology)
Janssen Pharmaceuticals Companies of J&J

Dr. Venkata Vepachedu is an experienced scientist and manger in molecular biology and biochemistry. He took his masters and Ph.D. in Biochemistry and Molecular Biology from Osmania University, India. After working as a post-doctoral fellow at UCONN Health Center, CT and Penn State University, PA he joined Pennsylvania Public Health Labs. Venkata worked in collaboration with Centers for Disease Control and Prevention (CDC) during the Zika outbreak. Later established the Next Generation Sequencing Laboratory for the Whole Genome Sequencing of the bacterial samples. Later he was offered Division Chief position of the Division of Virology and Immunology at the Maryland Department of Health Laboratories. At MDH Labs, he developed qPCR-based methods for the genotyping of different viral and bacterial pathogens, and for the WGS of the hepatitis, rabies, and SARS-CoV-2 viral genomes. He led the virology division during the tough times of COVID outbreak. Currently, Dr. Venkata is leading the newly formed Molecular Biology team in Janssen Pharmaceuticals, PA. His team works on the PCR based method development, validation and bioanalysis of gene therapy and cell therapy study samples. Dr. Venkata authored around 20 publications in peer-reviewed journals and several book chapters that include biodistribution analysis of clinical and non-clinical samples in gene and cell-therapy studies. Venkata loves melodious music, movies, travelling and meeting people.

Sumit Verma, M.E.M.

Senior Vice President Global Strategic Manufacturing
Iovance Biotherapeutics

Sumit Verma currently serves as Senior Vice President Global Strategy and Manufacturing for Iovance Biotherapeutics an immuno-oncology company that is pioneering a transformational approach to cure cancer by harnessing the human immune systems ability to recognize

and destroy diverse cancer cells in each patient. He has executive responsibilities for building a new cell therapy manufacturing facility, the Iovance Cell Therapy Center (iCTC), in The Navy Yard Philadelphia. He also formed the commercial manufacturing organization at iCTC that will be involved in providing novel cancer cell therapies across North America and Europe. Verma has successfully led commercial manufacturing teams in four new FDA-approved drug launches over the past 15 years. Prior to Iovance, he has had multiple leadership roles at Merck, Covidien, Mallinckrodt and most recently served as the Chief Operating Officer for Curium Pharmaceuticals. Sumit received his Bachelor of Science in Chemical Engineering from Lafayette College and Masters in Engineering Management from Washington University in St. Louis

Chuansong Wang, Ph.D., M.D.

Vice President of Process Sciences
Adverum Biotechnologies, Inc.

Lead gene therapy vector AAV development, tech transfer and manufacturing for Wet-AMD. Design and lead Process Performance Qualification (PPQ) in Adverum. First FDA approved gene therapy product Luxturna manufacturing platform development in Spark Therapeutics. 7 years Luxturna manufacturing and management, GMP and commercial production tech transfer and tech support. Luxturna manufacturing validation study for BLA. 10 years rAAV vector manufacturing and management in The Ohio State University (OSU) and Pfizer. 4 years postdoctoral training using rAAV as gene therapy vector for neurological disorders at OSU and Nationwide Childrens Hospital. 2 years Postdoctoral training in Brain and Cognitive Science at MIT MD and PhD degrees from China

Lijun Wang, Ph.D.

Chief Executive Officer
CoJourney Bio

Lijun has over twenty years' biotech industry experience, of which the most recent 17 years were focused on CGT viral vector and plasmid process development, process engineering and cGMP manufacturing. She has deep knowledge of multiple production platforms for viral vectors and plasmids. She specializes in large scale cell culture/fermentation and downstream purification of viral vectors and plasmids. She is an expert dedicated to bring bench scale processes to clinical and commercial ready.

Lili Wang, Ph.D.

Research Associate Professor
University of Pennsylvania

Dr. Lili Wang is a research associate professor and a research director at the Gene Therapy Program at the University of Pennsylvania. She has been in the field AAV gene therapy for over 25 years with extensive experience in the development of in vivo gene therapy for rare genetic diseases, including vector design & vector optimization, preclinical vector production, in vivo gene therapy in small and large animal models. Several of the preclinical programs she led have advanced to phase I - III clinical trials. Over the past 8 years, she has expanded her research interest to in vivo genome editing with CRISPRCas9 and meganuclease and demonstrated efficacy of in vivo genome editinggene targeting as novel treatment approaches for liver metabolic diseases in mouse models and nonhuman primates. In her talk, she will discuss her work on developing AAV gene therapy and in vivo genome editing to treat metabolic diseases in liver, such as OTC deficiency.



Xiao Wang, Ph.D.

Research Assistant Professor
University of Pennsylvania

Xiao Wang is a Research Assistant Professor of Cardiovascular Institute in the Perelman School of Medicine at the University of Pennsylvania. She received her B.S. in Biochemistry from Zhejiang University and Ph.D. degree in Molecular & Cell Biology from Chinese Academy of Sciences. After that, she was a Postdoctoral Fellow at Harvard University and the University of Pennsylvania. She has co-authored over 30 research papers. Her research focuses on the genetics of cardiovascular disease, seeks to identify genetic factors that cause or protect against disease, and uses novel genome-editing tools to develop new therapies. Most recently she extends her research interest to using novel genome-editing technologies to develop new ways to cure diseases caused by inherited mutations in the genome.

Lauren Woodard, Ph.D.

Assistant Professor
Vanderbilt University

Lauren Woodard, PhD, is an Assistant Professor of Medicine at Vanderbilt University Medical Center and of Biomedical Engineering at Vanderbilt University. Born in Houston, Texas, Dr. Woodard completed her B.S. in Biochemistry at the University of Texas at Austin as a Beckman Scholar in the laboratory of Dr. Karen Browning on translation initiation. After graduating with highest honors in 2004, Dr. Woodard completed her Ph.D. in 2009 in the interdisciplinary Cancer Biology program at Stanford University in the Genetics Department laboratory of Dr. Michele Calos where she studied the safety of phiC31 integrase for gene therapy. She moved back to Texas to begin her postdoctoral fellowship in the Baylor College of Medicine Division of Nephrology with Dr. Matthew Wilson, where she studied transposon function in mammalian cells and pioneered a novel technique to transfect adult mouse kidney. In 2013 she moved to Vanderbilt as a faculty Research Instructor and in 2015 she began her Career Development Award from the Department of Veterans Affairs. In 2018 she was appointed as a tenure-track Assistant Professor of Medicine at VUMC. Dr. Woodard is the Principal Investigator for the Woodard Lab and actively guides each of her lab members as they explore transposons, CRISPR, stem cells, and 3D culture models with the end goal of rapidly developing new models and regenerative treatments for patients with kidney disease.

Weichen Wu, Ph.D., RAC

Vice President, Global Regulatory Affairs
ASC Therapeutics

Dr. Weicheng Wu currently serves as the Vice President, Global Regulatory Affairs for ASC Therapeutics. In this role, he develops and implements regulatory strategies for gene therapy and gene editing programs for treatment of Hemophilia A. He has 20 years of broad experience in regulatory affairs, supporting the development of biologics, drugs, and medical devices. Previously, he worked as a Vice President of Regulatory Affairs at Fosun Pharma USA and at eVenus Pharmaceutical Laboratories (a Subsidary of Jiangsu Hengrui Medicine Co., Ltd.), a Director of Regulatory Affairs at Qualitest Pharmaceuticals, a Manager of Regulatory Affairs at Watson Pharmaceuticals, and a senior medical writer at Allergan. He obtained his B.S. degree in Biological Sciences and Biotechnology and M.S. degree in Biochemistry from Tsinghua University and his M.S. degree in Regulatory Science and Ph.D. degree in Biochemistry and Molecular Biology from the University of Southern California. He also holds Regulatory Affairs Certificates for US and EU.

Yang Xiang, Ph.D.

Senior Field Application Scientist
GenScript Biotech Corporation

Dr. Yang Xiang is an expert in the field of gene and cell therapy, with a Ph.D. from the Chinese Academy of Sciences and postdoctoral training at Harvard Medical School. He has held several positions in the biotech industry, including as a CTO of ABclonal, where he managed customer service across various fields for six years. During the COVID years, he led the development of an mRNA vaccine program at RVAC Medicines as a director. In 2023, Dr. Xiang joined GenScript as a Senior Field Application Scientist, focusing on gene and cell therapy. He is the first author of a Nature publication and holds U.S. patent on COVID. Dr. Xiangs diverse background positions him well to continue advancing the field.

Mandy Xie, Ph.D.

Executive Director
Cell Therapy Product & Analytical Development
Bristol Myers Squibb

Mandy possesses extensive expertise in CMC development across various modalities, ranging from Biologics to mRNA vaccines and Cell Therapy. Notably, she demonstrated exceptional leadership skills as she successfully led CMC team in preparing and submitting the BLA for Abecma, leading to the launch of the groundbreaking Multiple Myeloma CAR-T commercial product in 2021. Currently, Mandy assumes a pivotal role in leading the Product & Analytical Development for Cell Therapy programs at BMS. In her present capacity, she spearheads a team responsible for defining product Critical Quality Attributes (CQAs) through innovative correlative analysis, devising and implementing phase-appropriate analytical development and execution strategies for product control. The team's comprehensive support spans from preclinical stages to commercial operation, ensuring the seamless progression of Cell Therapy programs. Her team also dedicated signif-

icant efforts on automation to improve speed of product release. Prior to her involvement in the field of cell therapy, Mandy dedicated significant efforts to advance mRNA technology via non-viral delivery tools for vaccine development. Additionally, she amassed extensive experience in biologics development, specifically in CMC analytical development and control strategy.

Haishan Xiong, Ph.D., M.B.A.

Chief executive officer
Panorama Medicine

Combining strategic thinking, practical knowledge and passion, Haishan possesses industry insights and experience in execution. Haishan is CEO of Panorama Medicine, an early stage drug developer focusing on AI-assisted RNA splicing. Using this innovative discovery engine, Panorama has established a diverse portfolio. Before joining Panorama, Haishan was VP of Alliance at LianBio (NASDAQ LIAN), leading regulatory and clinical implementation of the companys diverse pipeline. Haishan obtained broad experience in drug development as CBO of KBP BioSciences (a clinical stage biotech) and SVP of ClinChoice (formerly FMD, a clinical CRO). Before moving into drug development, Haishan spent 12 years in drug commercialization at Roche and Spectrum Pharma. Haishan is active in the biosciences community. He is a member of the BayHelix Group and a former Executive Committee member of SAPA. Haishan holds a BS in Bioengineering from Nankai University, a PhD in Biochemistry from Penn State University, and MBA from The Wharton School University of Pennsylvania.

Steve Yang, M.S. M.B.A.

Co-Founder and Chief Executive Officer
Mianus Capital

Steve Yang is the co-founder and CEO of Mianus Capital, an investment firm founded in 2015, which focuses on early-stage innovations and tech-enabled service companies in life sciences. Mr. Yang has 20 years of experience in finance, technology, and management consulting. He previously held various management positions in banking and investment firms, including Nomura, Royal Bank of Scotland, and Black River Asset Management. He started his management career at McKinsey & Company. Mr. Yang earned an MBA with high distinction from the Ross School of Business at the University of Michigan. He also received a masters degree in Computer Science from the University of Minnesota.

Rongze Yang, Ph.D.

Director of Vector Engineering & Production
AAVnerGene Inc.

Dr. Rongze Yang received his medical degree in Internal Medicine and Ph.D. in Molecular Medicine from Sun Yat-sen University in China in 1994. He did his postdoctoral fellow training in molecular genetics and cell biology at University of Maryland School of Medicine in Baltimore and then joined the faculty as a research assistant professor in Department of Medicine. In 2017, he was recruited to Vigene Biosciences, a CDMO for manufacturing plasmid DNA and different viral vectors including AAV for research and clinical use. He initially served as Director of Plasmid Production, later as Director of Upstream Process Development & cGMP Manufacturing of Viral Vectors. After Vigene was acquired by Charles River Laboratories. Inc in 2021, he was promoted to Senior Director of Process Development to lead both upstream and downstream process development for vial vector production. In 2022, he joined AAVnerGene as director of vector engineering and viral vector production to develop new technologies for improving the efficacy of AAV manufacturing.

Pengfei Yuan, Ph.D.

Chief Technology Officer
EdiGene Inc

Dr. Yuan is the Chief Technology Officer, Head of Research at EdiGene. Dr. Yuan has extensive experience in the development and application research of gene-editing technology, especially in clinical translation and therapeutic development. Dr. Yuans research results have been published in Nature Biotechnology, Cell Research, Signal Transduction and Targeted Therapy either as a first or corresponding author. Dr. Yuan received his Ph.D. and Bachelors degrees in Biology from Peking University School of Life Sciences. He also has the title of Associate Researcher in the Beijing Natural Science Research Series.

Qinghua (Jenny) Zhao, M.S.

Executive Director
Forecyte Bio

Jenny has 25years experience in process development, scale-uptech transfer and cGMP operation on recombinant protein, antibody, plasmids and virus (AAV, Ad5, LV, RV) productions. She has being working on most of process unit operations from cell line development, large scale cell culture, fermentation, Chromograph, UFDF, to Fill & Finish. She also led an upstream process characterization leading to a BLA approval. Her current role is Executive Director of GMP operation including PD, GMP, supply chain and facility at Forecyte Bio, Maryland USA. Her previous role included Senior Director of Manufacture Science and Technology (MS&T) and Acting Director of Downstream Process Development at Vigene Biosciences, A Charles River Company (CDMO). She holds Master Degree in Chemical Engineering from University of Waterloo, Canada.

Haoyan (Michael) Zhou, Ph.D.

Research Formulation Lead
Spark Therapeutics

Haoyan(Michael) received his Bachelors degree from the Biomedical Engineering Department at Southeast University in China. He came to the USA for his MS degree at the University of Florida and Cornell University. He then obtained his Ph.D. degree focused on targeted drug delivery at Case Western Reserve University. He spent nearly five years at GlaxoSmithKlein in parenteral formulation and drug product development supporting varieties of modalities including small molecules, oligonucleotides and monoclonal antibodies. Currently, he leads the formulation team within discovery research at Spark Therapeutics to advance new therapeutic modalities for gene transfer. Haoyan has published 22 peer-review papers and two patents.

Huiyi Zhu, M.S.

Associate Director of Field Application Scientist
GenScript Probio

Huiyi Zhu is the Associate Director of Field Application Scientist at GenScript Probio, which is a biologics CDMO segment of GenScript. The company offers comprehensive services ranging from drug discovery to commercialization, providing proactive strategies, professional solutions, and efficient processes in the fields of antibody drug development, gene therapy, and cell therapy. Huiyi is a highly skilled expert in viral vector processes, with a wealth of experience in pharmaceutical manufacturing and development spanning over 10 years. During his previous career, Huiyi has excelled in project management, process development, and technology transfer. He has served as a subject matter expert and made significant contributions to the platform development of the groundbreaking gene therapy product Zolgensma previously, playing a key role to support the drug from clinical to commercial transition.

Peixin Zhu, Ph.D.

Vice President of Research & Development
Tevard Biosciences

Peixin Zhu joins Tevard Biosciences as the VP of R&D. He has about two decades of drug discovery and gene therapy development, experience ranging from developing A.I. HTS platforms for small molecules to advancing SMA Type I gene therapy through IND. He has a strong background across multiple scientific fields, including computational neuroscience, molecular biology, and gene therapies for CNS and liver indications including SMA, Dravet, Batten, DMD, Fabry, and Pompe diseases etc.. Prior to Tevard, Peixin was the VP of Discovery Research of LogicBio (NASDQ LOGC, acquired by AstraZeneca). Prior to joining LogicBio, Peixin Zhu led multiple teams at the Novartis Institutes for Biomedical Research Applied Genetic Technologies Corp. (NASDQ AGTC Acquired by Syncona) and Exegenesis Bio Inc. With leadership roles in R&D, he was responsible for establishing an in vivo A.I. HTS screening platform at Novartis, and for designing and bringing the 2nd generation SMA Type I gene therapy to early clinical stage at Exegenesis Bio. He and his team were also instrumental in several key partnerships including with the Stanley Center (Broad Institute), Florida State University.

LEADERSHIP TEAM & TRACK LEADS

Lu Wang, Ph.D., M.B.A.
Downstream Process Development Lead
Spark Therapeutics

Tao Niu, Ph.D.
Associate Director, Clinical & Quantitative Pharmacology
Vertex Pharmaceuticals

Yizhen Xu, M.D., Ph.D.
Vice President, Clinical Development
AskBio

Huize Yan, M.S.
Process Development Scientist
Spark Therapeutics

Saisi Xue, Ph.D.
Senior Scientist II, Analytical Development
Novelstar Pharmaceuticals

Jin Wen, Ph.D.
Senior Scientist, Analytical Development
Spark Therapeutics



Yufeng Li, Ph.D.
Executive Director of Clinical Development
Qilu Pharmaceuticals

Bill Lu, M.S., E.M.B.A.
Principal Consultant
Forerun Advantage

CJ (Chunjuan) Song, Ph.D.
Vice President CNS Disease Research and Pharmacology & Toxicology
ExegenesisBio Inc.

Fang Shen, Ph.D.
VP of Research & Translational Biology
Immunome

Jing Yang, Ph.D.
Chief Scientific Officer
BaseCure



Li Wan, Ph.D.
Senior Vice President, Head of Global Regulatory Affairs
GeneQuantum Healthcare



Yixuan Ming, Ph.D.
Scientist
Spark Therapeutics

WuXi Advanced Therapies

End to End Support for Cell and Gene Therapy



WuXi Advanced Therapies (WuXi ATU) is a global Contract Testing, Development and Manufacturing Organization (CTDMO) offering integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies.

DISCOVERY

- Optimized lentiviral and adeno-associated viral (AAV) vector design with our capsid & promoter discovery services
- Maximized vector yield with best in class transient lentiviral and AAV expression platforms
- State of the art automation platforms for high throughput cell line development and screening
- Scalable viral vector manufacture with TESSA™ technology and Lenti VV stable cell lines



PLASMIDS

- Custom plasmid design and engineering using OXGENE's patented SnapFast™ technology at research, clinical GMP and commercial GMP grade
- OXGENE's optimised AAV and lentiviral packaging plasmids in stock at research, clinical GMP and commercial GMP grades
- Expedited international delivery off-the-shelf plasmids delivered within 2 weeks, up to 50g GMP grade bespoke plasmids delivered internationally within 3 months.
- Antibiotic-free manufacture to ensure regulatory compliance

TESTING

- Integrated testing for all manufacturing customers to accelerate turnaround times
- New 140,000 ft² laboratories to triple capacity for both integrated and external testing clients
- Strong assay development capabilities & expertise in molecular, virology, microbiology and analytical testing
- Biosafety testing, raw material testing, in-process and product release testing for cell & gene therapy clients
- Commercial lot release programs
- Full regulatory support for global product submission and maintenance

MANUFACTURING

- Established track record in early/late-stage clinical manufacturing
- Accelerated time to clinic (12 – 15m) with optimized GMP manufacturing platforms for viral vectors & cell therapies
- Consistent and reliably high viral vector yield and quality across platforms
- Fully stocked supply chain due to in-house plasmid banking and manufacture at all grades
- Phase-appropriate quality assurance to ensure balance of speed and compliance

Get in touch at **info_ATU@wuxiapptec.com**
For more information, please visit **advancedtherapies.com**

To view more, visit:
advancedtherapies.com

Bring your life-saving therapies to market faster, with confidence

Explore our knowledge hub to see how we can advance your cell and gene therapy development.

Here's what you'll find:

- Scalable digital PCR solutions and standardized workflows for:
  - Absolute quantification of AAV genome titers
  - Robust detection of residual host cell DNA contaminants
  - Confirmation of CRISPR-mediated editing events in CAR-T cells
- Grants and partnerships to help grow your business
- Bespoke packages and services to address your company's needs

Visit **www.qiagen.com/pharma-biotech** or scan the QR code to learn more.

Sample to Insight

Pioneering Your Pathway to Breakthroughs in Cell and Gene Therapy

Venture into the future of advanced therapies with us!
Whether you are in the early stages of pre-clinical development or ramping up for large-scale manufacturing, our capabilities are designed to scale with your needs. Leverage our technical expertise, scale-up experience and continuous innovation to accelerate your journey to market.

BIOLOGICS
PLASMID
VIRAL VECTORS
VACCINES
MRNA
ADC

GenScript PROBIO
Innovation through Collaboration

Learn more about us at **genscriptprobio.com**

AAVnerGene's innovations include **ATHENA**, a platform for serotype selection, engineering, and screening, as well as **AAVone**, a new system for increasing yields and simplifying AAV production . Our goal is to make AAV gene therapy more efficient and accessible to all by introducing new solutions to bottleneck problems in gene therapy.

AAVnerGene
Together We Find The Cures

Please scan the QR codes below to learn more about our products, services, and newest innovations.

Company Brochure

AAV Packaging and Production
Process Development and Optimization
Library Construction, Production, and Screening

Our poster presentations at the annual meeting for the **American Society for Cell and Gene Therapy 2023**:

AAVone

An All-in-One Plasmid System for Efficient AAV Production

ATHENA

Platform for AAV Capsid Selection, Comparison, and Evolution

Potential collaborators and investors are invited to contact our President and CEO at
daozhan.yu@aavnergene.com

9620 Medical Center Drive Suite 100 Rockville, MD 20850
www.aavnergene.com

Next Generation CRO & Central Lab

CLIA/CAP Accredited Local Laboratory

iCura DIAGNOSTICS

107 Great Valley Parkway
Malvern, PA 19355 visit us at www. icuradx.com
(484) 588 6055

Cell Therapy Viral titer quantification, detection lentiviral targets, residual DNA quantification assays, etc.

Gene Therapy rAAV assay, Viral titer quantification, residual DNA quantification assays, Rapid Bioburden Assay, etc.

Genomics services NGS, Digital PCR, qPCR, qPCR, RNAseq, FFPE tumor profiling, ctDNA, cfDNA ...

Biomarker Anti-CRISPR/CAS9 antibody ELISA assays

Histology, Spatial Biology, Tumor Microenvironment, Singleplex & Multiplex IHC/IF, FISH, CIS

Logistics services, kitting, shipping, sample tracking, lab manual, site training ...

Team of Highly Specialized PhD Scientists and Board-certified Pathologists, Hematopathologist on site

Your One-stop CDMO-Plus Service Provider for Cell & Gene Therapy

uBriGene

About us: *uBriGene Bioscience Inc. is a leading contract development and manufacturing organization (CDMO), specializing in development and application of cell and gene therapy technologies. uBriGene provides clients with end-to-end cell and gene therapy support.*

In May 2023, uBriGene expanded into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.



Visit our Website & LinkedIn

Scheer Partners
丰硕成果赢得卓著声誉

为何选择 SCHEER PARTNERS?

L500余宗 实验室交易

$30亿 丰硕成果赢得卓著声誉

110万m2 实验室交易面积

TIM CONREY
执行董事兼区域总监
tconrey@scheerpartners.com

LISA BERGER BASKIN
高级副总裁
lbaskin@scheerpartners.com

KJ KULIK
高级顾问
kkulik@scheerpartners.com

LOU TONON
高级顾问
ltonon@scheerpartners.com

scheerpartners.com 610-368-3851

地址：50 S 16th Street, Suite 1700, Philadelphia, PA 19102

科研房地产服务

Certified Public Accountants

- *Business formation and type election*
- *Tax return preparation and filing*
- *Payroll processing and reporting*
- *Bookkeeping and account advisory*
- *Financial statements preparation*
- *Tax planning and business consulting*
- *Business credit and deduction claim*
- *International business tax reporting*
- *Cash flow budgeting and forecasting*

For thirty years, Weinstein and Spellman LLC has been providing quality, personalized financial guidance to domestic and international individuals and businesses. We guide our clients through a full range of tax planning and financial decisions with strategies that minimize tax liabilities, maximize cash flow and keep the clients on track to their financial goals.

Accounting and Tax planning | About us

Weinstein and Spellman LLC

14 Commerce Drive Ste 304
Cranford, NJ 07016
(973)727-2808 (Mindy)
accountant@weinsteinspellman.com
www.weinsteinspellman.com

Map


GLADWYNE
Frazer
BRYN MAWR
Devon
BERWYN
Ardmore
STRAFFORD
Paoli
Haverford
Kiosk
MALVERN
Centennial Ballroom III
EXECUTIVE BOARDROOM
ST DAVIDS
Centennial Ballroom II
Centennial Ballroom I
WAYNE
VILLANOVA
Grand Ballroom
Main Entrance